ESA anemia correction × improved survival during head-and-neck cancer radiotherapy: evidence checklist

Required evidence, verification status and materials actually read
Item	AVerification status	BReading scope	CReview item	DCurrent findings	EWhy unverified	FRequired materials and conditions	GFurther research
1	Partly verified	Full text not readStored summary read	N01 · Efficacy comparison and presentation of stored materialDoes the selected question concern improved survival or the parent tumor-control question?Required	The selected question is 'Improved survival', with original grade F and a note that disease-specific and overall death both significantly favored harm. The parent asks about improved locoregional tumor control and has F12, Warning and original assessment axes. The selected record has no score, status or axes. S01 S02 S03 S04	Only the corresponding preserved-summary information was recorded; detailed original materials remain unread and existing content review is incomplete. The subclaim originally has no score, status or axes, and no new survival verdict was made. Existing content review remains incomplete.	Preserve the survival subclaim, grade and note separately from the parent tumor-control claim, score and axes	Proposal: Track survival and tumor-control materials separately; the record includes no new search, calculation or trial.
2	Partly verified	Full text not readStored summary read	N02 · Efficacy comparison and presentation of stored materialWhat events and directions do the survival measures represent?Required	The original account describes harm for DAHANCA10 disease-specific death, HR1.43 (95% CI1.08~1.90), and overall death, HR1.30 (1.02~1.64). EFS HR1.36 (1.09~1.69) and locoregional failure HR1.53 (1.16~2.02) are different outcomes. ENHANCE 'survival RR1.39' and the review's OS Peto OR0.73 retain their separate original names and directions. S01 S02 S04	Only the corresponding preserved-summary information was recorded; detailed original materials remain unread and existing content review is incomplete. Exact death/survival event coding and some estimator and analysis definitions cannot be fully verified from the summary. Existing content review remains incomplete.	Exact names and directions of death, survival, event-free survival and tumor control	Proposal: Link endpoint-specific event coding and comparison directions; the record includes no new search, calculation or trial.
3	Partly verified	Full text not readStored summary read	N03 · Efficacy comparison and presentation of stored materialWhat population, study exposure and comparator did DAHANCA10 use?Required	The summary describes DAHANCA10 as a multicenter open-label randomized phase 3 comparison of weekly darbepoetin during head-and-neck cancer radiotherapy with hemoglobin <14.0g/dL. This is historical trial exposure, not an instruction on drug choice, substitution or use. S01	Only the corresponding preserved-summary information was recorded; detailed original materials remain unread and existing content review is incomplete. Details of cancer site/stage, baseline anemia, concurrent treatment, exact control management and exposure stopping conditions remain unverified. Existing content review remains incomplete.	Actual cancer/anemia and radiotherapy population and the two arms' historical study conditions	Proposal: Link survival materials by population and comparison conditions; the record includes no new search, calculation or trial.
4	Partly verified	Full text not readStored summary read	N04 · Efficacy comparison and presentation of stored materialHow do DAHANCA10 planned, randomized and evaluable denominators differ?Required	The original denominators were planned600, stopping after522 randomized, and513 evaluable (254/259). The513 is not automatically assigned to every survival or safety analysis, and no missing-person counts or proportions are newly calculated. S01	Only the corresponding preserved-summary information was recorded; detailed original materials remain unread and existing content review is incomplete. Reasons for exclusion between randomized and evaluable groups, survival-specific ITT/follow-up denominators and arm-specific missingness remain unverified. Existing content review remains incomplete.	Roles of planned600, randomized522, evaluable513 and254/259	Proposal: Separate analysis populations and exclusion reasons by denominator; the record includes no new search, calculation or trial.
5	Partly verified	Full text not readStored summary read	N05 · Efficacy comparison and presentation of stored materialWhat plan and criteria governed interim stopping?Required	The original DAHANCA10 account reports stopping at522 after a planned interim analysis found inferiority in the experimental arm. Planned600, actual522 and evaluable513 have different roles; no new effect correction for early stopping is made. S01	Only the corresponding preserved-summary information was recorded; detailed original materials remain unread and existing content review is incomplete. Interim timing/threshold, alpha spending, committee decisions and survival follow-up after stopping remain unverified. Existing content review remains incomplete.	Prespecified interim analysis, inferiority stopping threshold and follow-up plan	Proposal: Document the relationship between interim analysis and final survival outcomes; the record includes no new search, calculation or trial.
6	Partly verified	Full text not readStored summary read	N06 · Efficacy comparison and presentation of stored materialWhat is the hierarchy of the primary tumor-failure endpoint and selected survival outcomes?Required	DAHANCA10's primary endpoint was time to locoregional failure. Five-year cumulative locoregional failure47% versus34% and HR1.53 (1.16~2.02) retain their original scope. They are not relabeled as a survival primary endpoint or five-year overall-death incidence. S01	Only the corresponding preserved-summary information was recorded; detailed original materials remain unread and existing content review is incomplete. Prespecified hierarchy, multiplicity and individual analysis timepoints for EFS, disease-specific death and overall death remain unverified. Existing content review remains incomplete.	Primary endpoint, secondary survival outcomes, prespecified analysis hierarchy and multiplicity	Proposal: Link endpoint hierarchy and prespecified multiple-comparison plans; the record includes no new search, calculation or trial.
7	Partly verified	Full text not readStored summary read	N07 · Efficacy comparison and presentation of stored materialWhat analysis produced the DAHANCA10 disease-specific death result?Required	Disease-specific death HR1.43 (95% CI1.08~1.90) retains its original name and harm direction. It is not converted into an overall-death HR, survival proportion or absolute death rate. S01	Only the corresponding preserved-summary information was recorded; detailed original materials remain unread and existing content review is incomplete. Cause adjudication, competing-death handling, original event counts, denominators, follow-up time, original P value and model details remain unverified. Existing content review remains incomplete.	Cause-of-death definition, denominator, time, HR/CI and handling of competing events	Proposal: Link endpoint definitions and competing-event/survival-analysis materials; the record includes no new search, calculation or trial.
8	Partly verified	Full text not readStored summary read	N08 · Efficacy comparison and presentation of stored materialWhat analysis produced the DAHANCA10 overall-death result?Required	Overall death HR1.30 (95% CI1.02~1.64) is recorded as in the preserved material. It is a separate endpoint from disease-specific death HR1.43 and is not reversed into support for improved survival. S01	Only the corresponding preserved-summary information was recorded; detailed original materials remain unread and existing content review is incomplete. Overall-death event counts, denominators, exact follow-up duration, censoring/missingness, model/covariates and original P value remain unverified. Existing content review remains incomplete.	Overall-death HR/CI, events/people, follow-up duration and analysis population	Proposal: Document overall-death follow-up and analysis in the randomized population; the record includes no new search, calculation or trial.
9	Partly verified	Full text not readStored summary read	N09 · Efficacy comparison and presentation of stored materialCan EFS be substituted for survival or cancer-specific death?Required	DAHANCA10 EFS HR1.36 (1.09~1.69) is a separate event-free survival outcome in the original account. It is not merged with locoregional failure, disease-specific death or overall death, and no component events are invented. S01	Only the corresponding preserved-summary information was recorded; detailed original materials remain unread and existing content review is incomplete. Exact composite EFS components, first-event rule, denominator and timepoint remain unverified in the summary. Existing content review remains incomplete.	Link event-free survival event composition, hierarchy and analysis separately	Proposal: Document the composite endpoint and its components separately; the record includes no new search, calculation or trial.
10	Partly verified	Full text not readStored summary read	N10 · Efficacy comparison and presentation of stored materialMay the five-year tumor-failure timepoint be assigned to every survival outcome?Required	DAHANCA10's five-year timepoint belongs to cumulative locoregional failure47%/34%. It is not assigned arbitrarily to the disease-specific death, overall-death or EFS HRs. S01	Only the corresponding preserved-summary information was recorded; detailed original materials remain unread and existing content review is incomplete. Survival-HR-specific median follow-up, end time, censoring and period-specific risk remain unverified. Existing content review remains incomplete.	Actual endpoint-specific follow-up and distinction between absolute and time-to-event outcomes	Proposal: Separate time scopes by endpoint in follow-up materials; the record includes no new search, calculation or trial.
11	Partly verified	Full text not readStored summary read	N11 · Efficacy comparison and presentation of stored materialHow might an open-label study and outcome assessment affect individual endpoints?Required	The original account describes DAHANCA10 as an open-label randomized study without uniform central blinded imaging assessment. Tumor-control assessment and overall-death ascertainment are not assumed to share the same measurement error. S01	Only the corresponding preserved-summary information was recorded; detailed original materials remain unread and existing content review is incomplete. Allocation concealment, cause-of-death adjudication, death follow-up/missingness and blinding of survival ascertainment remain unverified. Existing content review remains incomplete.	Record allocation, open-label status, tumor assessment and death ascertainment separately	Proposal: Link endpoint-specific measurement and missingness materials; the record includes no new search, calculation or trial.
12	Partly verified	Full text not readStored summary read	N12 · Efficacy comparison and presentation of stored materialHow were concurrent treatment and deviations reflected in survival estimates?Required	The original account compares ESA anemia correction during radiotherapy and retains DAHANCA10's open-label randomized design. Details of study exposure, actual transfusion, additional ESA, radiotherapy/chemotherapy and deviations are not filled in. S01	Only the corresponding preserved-summary information was recorded; detailed original materials remain unread and existing content review is incomplete. Arm-specific actual exposure, concurrent treatment, crossover/adherence, adjustment variables and survival ITT/PP analysis specifications remain unverified. Existing content review remains incomplete.	Radiotherapy, concomitant treatment, crossover/adherence, ITT/PP and covariates	Proposal: Document concurrent treatment and comparison estimators; the record includes no new search, calculation or trial.
13	Partly verified	Full text not readStored summary read	N13 · Efficacy comparison and presentation of stored materialDoes successful hemoglobin correction imply improved survival?Required	The parent advertising and interpretation text distinguishes anemia correction from survival/tumor control during cancer treatment. Hemoglobin correction itself is not transferred into survival benefit, and the selected record's death-harm note is preserved. S01 S02 S03	Only the corresponding preserved-summary information was recorded; detailed original materials remain unread and existing content review is incomplete. Trial-specific hemoglobin changes, reduced-transfusion values and prespecified mediation analyses relating these to survival remain unverified in this summary. Existing content review remains incomplete.	Distinguish anemia/hemoglobin surrogates from clinical survival events	Proposal: Document surrogate measures and clinical events separately; the record includes no new search, calculation or trial.
14	Partly verified	Full text not readStored summary read	N14 · Efficacy comparison and presentation of stored materialHow do the ENHANCE comparison and denominators differ from DAHANCA10?Required	ENHANCE reports a multicenter randomized double-blind placebo comparison with351 participants, epoetin beta180/placebo171, and ITT. These are not treated as the same arms, formulation or522/513 denominators as DAHANCA10 darbepoetin. S02	Only the corresponding preserved-summary information was recorded; detailed original materials remain unread and existing content review is incomplete. Baseline conditions, exact dose/duration, survival-specific observation/censoring, concurrent treatment and analysis details remain unverified. Existing content review remains incomplete.	Scope of epoetin beta, blinded placebo comparison,351/180/171 and ITT	Proposal: Separate population, formulation and comparison differences; the record includes no new search, calculation or trial.
15	Partly verified	Full text not readStored summary read	N15 · Efficacy comparison and presentation of stored materialWhat does ENHANCE survival RR1.39 mean?Required	ENHANCE reports a harm direction for survival RR1.39 (95% CI1.05~1.84). Its original primary locoregional progression-free survival adjusted RR1.62 (1.22~2.14), P=.0008, is separate. Survival RR is not renamed HR, death HR or absolute death rate, and no reciprocal is calculated. S02	Only the corresponding preserved-summary information was recorded; detailed original materials remain unread and existing content review is incomplete. Exact survival-RR event/control coding, time, model, denominator/events and original P value remain unverified. Existing content review remains incomplete.	Original 'survival RR' coding, direction and CI, separate from the tumor primary endpoint	Proposal: Document the original estimator name and comparison direction; the record includes no new search, calculation or trial.
16	Partly verified	Full text not readStored summary read	N16 · Efficacy comparison and presentation of stored materialDo the initial and long-term RTOG99-03 reports concern the same trial?Required	The initial and long-term RTOG99-03 reports are linked to the same148-participant randomized trial. The original citation contains PMID17716826 and25670542, with the URL pointing to the25670542 long-term report. The reports are not added as separate independent trials or new participants. S03	Only the corresponding preserved-summary information was recorded; detailed original materials remain unread and existing content review is incomplete. Exact participant flow, endpoint-specific follow-up and links between original bibliography and materials remain unread externally. Existing content review remains incomplete.	Relationship of original trial/follow-up reports,148 participants, bibliography and timepoints	Proposal: Document time-specific reports from the same cohort; the record includes no new search, calculation or trial.
17	Partly verified	Full text not readStored summary read	N17 · Efficacy comparison and presentation of stored materialWhat are the periods and effects for RTOG survival and tumor failure?Required	RTOG99-03 reports three-year locoregional failure44% versus36%, P=.56, and five-year46.2% versus39.4%, P=.42. OS36.9% versus38.2%, P=.54, is a separate survival outcome. No exact OS period is invented, and nonsignificance is not treated as zero effect, equivalence or certified exclusion of an important survival benefit. S03	Only the corresponding preserved-summary information was recorded; detailed original materials remain unread and existing content review is incomplete. Exact OS timepoint, CI, events/denominators, censoring, power and estimation model remain unverified in the summary. Existing content review remains incomplete.	OS, three-/five-year locoregional failure, original P values and limits of nonsignificance	Proposal: Link time-specific tumor/survival outcomes and precision materials; the record includes no new search, calculation or trial.
18	Partly verified	Full text not readStored summary read	N18 · Efficacy comparison and presentation of stored materialWhat are the direction and analysis denominators of the Cochrane survival OR?Required	The2009 Cochrane review preserves OS Peto OR0.73 (95% CI0.58~0.91) and locoregional progression-free survival OR0.63 (0.49~0.80), in the context of5RCTs and1,397 participants. The original account describes radiotherapy+EPO as worse than radiotherapy alone and OR<1 as favoring radiotherapy alone. No reciprocal, new HR or absolute effect is produced. S04	Only the corresponding preserved-summary information was recorded; detailed original materials remain unread and existing content review is incomplete. Endpoint-specific event coding, actual included denominators, models/weights, original P values and trial mapping remain unverified. Existing content review remains incomplete.	Names/coding of5RCT1397 participants, OS Peto OR and other pooled endpoints	Proposal: Document pooled-endpoint comparison directions and included denominators; the record includes no new search, calculation or trial.
19	Partly verified	Full text not readStored summary read	N19 · Efficacy comparison and presentation of stored materialHow much do the review and individual reports overlap?Required	DAHANCA10, ENHANCE, RTOG99-03 and the Cochrane5-trial1,397-participant review are distinguished at report, trial-family and synthesis levels. The review inclusion list and time-specific overlap remain unverified. The three reports are not added to the5 trials, and1397,522,351 and148 are not summed. S01 S02 S03 S04	Only the corresponding preserved-summary information was recorded; detailed original materials remain unread and existing content review is incomplete. Included-trial lists, follow-up mappings, endpoint-specific overlap/exclusions and unique clinical totals remain unverified. Existing content review remains incomplete.	Cross-links between review-included trials/follow-up reports and the three individual trials	Proposal: Describe shared/overlapping relationships between synthesis and direct reports; the record includes no new search, calculation or trial.
20	Partly verified	Full text not readStored summary read	N20 · Efficacy comparison and presentation of stored materialHow do formulation, population and duration differences relate to the selected scope?Required	DAHANCA10 open-label darbepoetin comparison, ENHANCE placebo-controlled epoetin beta, RTOG99-03 epoetin alfa conditions and the review's mixture are preserved separately. Original RX/I1 and historical investigator-independence statements are not inherited as current independent-replication certification. S01 S02 S03 S04	Only the corresponding preserved-summary information was recorded; detailed original materials remain unread and existing content review is incomplete. Unique replication counts under the same selected conditions, formulation equivalence, arm-specific effect modification and review heterogeneity details remain unverified. Existing content review remains incomplete.	Differences in ESA/arms/periods, denominators and analyses, with independence unverified	Proposal: Link replication/heterogeneity materials while separating different conditions; the record includes no new search, calculation or trial.
21	Partly verified	Full text not readStored summary read	N21 · Harm-information gaps supplementing the efficacy tableHow do cancer-survival harm and other safety outcomes differ?Supplementary	Cancer-survival/tumor-control harm is central in the original account. The statement that DAHANCA10 found no excess serious adverse events, cardiovascular events or acute/late radiation toxicity is separate. Absence of other safety signals is not rewritten as overall safety or absence of cancer harm. S01	Only the corresponding preserved-summary information was recorded; detailed original materials remain unread and existing content review is incomplete. Definitions, ascertainment, events/denominators, exposure/follow-up, missingness and precision for individual safety outcomes remain unverified. Existing content review remains incomplete.	Separate definitions and analysis scopes for death/cancer outcomes, SAE, cardiovascular events and radiation toxicity	Proposal: Separate cancer outcomes and other safety events; the record includes no new search, calculation or trial.
22	Unverified	Full text not readStored summary read	N22 · Harm-information gaps supplementing the efficacy tableAre death causes, missingness, vulnerable groups and long-term scope verified?Supplementary	The selected question preserves disease-specific and overall death separately and uses the original overall-death HR/CI. Long-term survival, vulnerable groups and cancer-site/stage results are not filled with values absent from the preserved materials. S01 S02 S03	Currently required information remains unverified in the preserved summary. Cause adjudication, competing events, arm-specific follow-up loss, periods beyond follow-up and prespecified subgroups remain unverified. Existing content review remains incomplete.	Death ascertainment, cause, competing events, follow-up loss and vulnerable-group specifications	Proposal: Separate time- and vulnerable-group-specific evidence gaps in follow-up materials; the record includes no new search, calculation or trial.
23	Partly verified	Full text not readStored summary read	N23 · Efficacy comparison and presentation of stored materialWhat is the scope of DAHANCA10 support and investigator roles?Required	The original account describes Danish Cancer Society and Amgen support, free Aranesp from Amgen and Amgen bearing most GCP/quality-control costs. Its investigator-driven statement, no Amgen role in design/conduct/collection/analysis, and an opportunity for manuscript comments without comments provided are preserved as history. S01	Only the corresponding preserved-summary information was recorded; detailed original materials remain unread and existing content review is incomplete. Support agreements, actual decision-making, employee authors, author-specific COI, other publication costs and original disclosures remain unread externally. Existing content review remains incomplete.	Distinguish cash, free products, quality-control costs, study/manuscript roles and COI	Proposal: Separate types of support and study/manuscript roles; the record includes no new search, calculation or trial.
24	Partly verified	Full text not readStored summary read	N24 · Efficacy comparison and presentation of stored materialDo ENHANCE, RTOG and review support have the same meaning?Required	ENHANCE F.Hoffmann-LaRoche and RTOG NCI/OrthoBiotech support are preserved separately. Mixed public/company support statements for the Cochrane review and included trials are not transferred into verification of the review's own funding or COI. S02 S03 S04	Only the corresponding preserved-summary information was recorded; detailed original materials remain unread and existing content review is incomplete. Free products, employee authors, actual roles and COI for each report, and the review's own funding/COI remain unverified. Existing content review remains incomplete.	Funding, products, employees and COI for each company/public/review source	Proposal: Link direct-trial and review support separately; the record includes no new search, calculation or trial.
25	Partly verified	Full text not readStored summary read	N25 · Efficacy comparison and presentation of stored materialHow do registration wording, actual registration identity and plans differ?Required	The DAHANCA10/ENHANCE statement 'predates registration systems, so none exists' is historical wording with actual identifiers unrecorded. RTOG's NCT00004917 retains only the original identifier. The review's 'not applicable' is not treated as certified absence of clinical registration. S01 S02 S03 S04	Only the corresponding preserved-summary information was recorded; detailed original materials remain unread and existing content review is incomplete. Actual registration text, change history, prespecified endpoints/follow-up, protocol and SAP are unread, with no access attempt. Existing content review remains incomplete.	Preserve original registration wording/identifiers separately from unread status	Proposal: Link registration/plan histories by report; the record includes no new search, calculation or trial.
26	Partly verified	Full text not readStored summary read	N26 · Harm-information gaps supplementing the efficacy tableDoes the FDA warning account reflect actual reading of the original label?Supplementary	The parent account contains an FDA warning that ESAs may shorten survival or increase tumor progression/recurrence in head-and-neck and other cancers. The FDA label remains unread in this work; no separate URL was provided in the preserved summary, so no address is invented. S01	Only the corresponding preserved-summary information was recorded; detailed original materials remain unread and existing content review is incomplete. Label version, actual warning text, indications/exceptions and update date remain unverified. Existing content review remains incomplete.	Separate the account's warning history from external FDA label/date/scope	Proposal: Link the original warning account to version-specific sources; the record includes no new search, calculation or trial.
27	Partly verified	Full text not readStored summary read	N27 · Efficacy comparison and presentation of stored materialDoes the reduced-transfusion account for another indication answer cancer survival?Required	The contextual2925 citation refers to a B72 account of reduced red-cell transfusions in very-low-birth-weight preterm infants. That indication and transfusion endpoint differ from cancer survival here. The citation is not turned into a direct survival trial, new RCT or opposite survival effect. S05	Only the corresponding preserved-summary information was recorded; detailed original materials remain unread and existing content review is incomplete. That account's original text/trial and any direct link to these materials remain unread in this work. It is not substitute evidence for the selected survival question. Existing content review remains incomplete.	Distinguish the preterm-infant2925 citation from the selected head-and-neck cancer survival question	Proposal: Separate source relationships for different indications; the record includes no new search, calculation or trial.
28	Partly verified	Full text not readStored summary read	N28 · Efficacy comparison and presentation of stored materialCan these findings be extended to CKD, other cancers or anemia conditions?Required	This sheet concerns survival with ESA anemia correction during head-and-neck cancer radiotherapy. Other anemia indications and preterm-infant transfusion context in the account are not transferred into head-and-neck cancer survival outcomes or extended into new effect/contraindication verdicts for every ESA indication. S01 S02 S03 S05	Only the corresponding preserved-summary information was recorded; detailed original materials remain unread and existing content review is incomplete. Direct survival materials for other indications, anemia severity, target hemoglobin and treatment combinations are outside this production scope and remain unverified. Existing content review remains incomplete.	Boundary between original head-and-neck cancer radiotherapy scope and other indications	Proposal: Separate condition-specific questions and direct-material scope in follow-up materials; the record includes no new search, calculation or trial.
29	Partly verified	Full text not readStored summary read	N29 · Efficacy comparison and presentation of stored materialHow are preserved summaries and actual external reading displayed?Required	The full preserved summary's Korean/English text, evidence, citations and subclaims were read for production and preserved. Each preserved JSON summary is shown as 'summary read'; external papers, registration, plans and support materials are 'unread'. Bibliography, URLs, registration numbers and historical review statements do not prove external reading in this work. S01 S02 S03 S04 S05	Only the corresponding preserved-summary information was recorded; detailed original materials remain unread and existing content review is incomplete. External abstracts, full texts, registration, plans and COI are unread with no access attempt; source-link operation was not tested. Existing content review remains incomplete.	Access status of summaries, external originals, registration, protocol, SAP and COI	Proposal: Record actual acquisition/reading levels and versions by material; the record includes no new search, calculation or trial.
30	Partly verified	Full text not readStored summary read	N30 · Efficacy comparison and presentation of stored materialHow are original Korean/English text, reference date, empty values and correction history retained?Required	The parent Korean/English text, axes, F12, Warning,2026-08-26, empty corrections array and empty deliberation string are preserved in the full summary copy. The selected record retains F, note and English wording; absent score/status/axes are not filled from the parent. Absent facet values are not filled with new content. S01 S02 S03 S04 S05	Only the corresponding preserved-summary information was recorded; detailed original materials remain unread and existing content review is incomplete. No external update, detailed translation content review or additional correction was performed in this original record. Existing content review remains incomplete.	Preserve original languages,2026-08-26, empty correction/deliberation values, false and unrecorded values	Proposal: Link sources/dates of the original version and new production content; the record includes no new search, calculation or trial.
31	Partly verified	Full text not readStored summary read	N31 · Efficacy comparison and presentation of stored materialAre condition application, table production and completed content review separate events?Required	Conditions were saved before recording the frozen production event and a separate application time to create the table. The original model/content/boundary review-pending flags are false, completion is also false, and existing content review remains incomplete. Table production and material-slot counts do not certify clinical review or unique trial/independent participant counts. S01 S02 S03 S04 S05	Only the corresponding preserved-summary information was recorded; detailed original materials remain unread and existing content review is incomplete. Existing full content review remains incomplete; QA, screen and link tests were not performed in the original production event. Existing content review remains incomplete.	Distinguish conditions saved first, freezing, separate application and existing content-review status	Proposal: Record production versions and user correction comments as history; the record includes no new search, calculation or trial.

No items match your search or filter.

31 itemsWhat the statuses mean

Assessment scope

Stored-material review date: Not recorded
Original evidence cut-off: 2026-08-26
Scope actually checked: Existing review summaries and stored records of methodological application. Full papers, supplements, registrations, plans and original data were not read.
What the dates mean: This is the date the stored materials were checked, not the date of a new search of the clinical literature.
Population: Head-and-neck cancer radiotherapy populations and anemia/hemoglobin conditions of each original trial; not extended to other indications or diseases
Ingredient, formulation and route: ESA anemia correction during head-and-neck cancer radiotherapy; historical trial exposure to trial-specific darbepoetin/epoetin formulations
Dose: Not recorded
Comparator: Original control, placebo or comparison management in DAHANCA10, ENHANCE and RTOG99-03; the review's pooled comparison is separate
Measured outcome: Improved survival in the selected existing question; disease-specific death, overall death and OS retain their original names, directions, periods and denominators
Duration: Original trial-specific survival analysis timepoints and follow-up; the DAHANCA10 five-year locoregional-failure timepoint is not assigned to all survival HRs
Questions outside this scope: Promoting the parent tumor-control primary endpoint to the selected survival primary endpoint, or transferring anemia correction into survival benefit; Renaming death HR, survival RR or OS Peto OR, taking reciprocals, or producing new effects, CIs or absolute risks; Assigning DAHANCA10's five-year locoregional-failure timepoint to all survival HRs; Calculating new exclusions, incidence or survival/safety denominators from planned600, randomized522 and evaluable513 (254/259); Adding ENHANCE351/180/171, RTOG148 and the review's5RCT1397 into independent-trial or total-participant counts; Counting initial/long-term RTOG reports, arms, endpoints or timepoints as new independent trials, or inventing the exact OS period; Treating RTOG nonsignificance as zero effect, equivalence or certified exclusion of an important survival benefit; Transferring preterm-infant2925 B72, CKD or other-indication outcomes into direct head-and-neck cancer survival effects; Changing absence of other SAE, cardiovascular or radiation-toxicity signals into overall safety or absence of cancer-survival harm; Presenting the account's FDA warning as reading/accessing the latest label or as new guidance; Changing original registration-system-era absence/not-applicable wording into an actual registration identifier or current verification of registration absence; Inheriting parent scores/axes, historical cross-checks or support/independence accounts as subclaim values, current content review or independence certification; New numerical calculations, hypothetical values, new grades/evidence or patient drug choice, substitution, use, treatment or dosing guidance

Evidence and sources

The links below lead to the sources. A link alone does not mean the original source was read or its latest publication status verified.

S01 · Overgaard J et al. 2018 DAHANCA 10

PubMed

Material type: Multicenter open-label randomized phase 3 trial
Materials actually read: Summary read; external material unread
Findings recorded in the stored summary: Disease-specific death HR1.43 (95% CI1.08~1.90) and overall death HR1.30 (1.02~1.64) retain their original harm direction. EFS HR1.36 (1.09~1.69) and five-year locoregional failure47% versus34%, HR1.53 (1.16~2.02), are different endpoints. Five years is not assigned to every survival HR, and death rates, differences or CIs are not newly calculated.
Record level: Outcome wording in the stored summary
Study overlap and independent replication: S01 DAHANCA10/Overgaard2018 is an open-label randomized phase3 report with planned600, randomized522 and evaluable513 (254/259). Primary locoregional failure, EFS, disease-specific death and overall death are separate. The same report, arms, people, endpoints or sibling sheets are not counted as new independent trials or participants. Report/material slots are not unique clinical trial, participant or independent-replication totals; clinical totals remain unrecorded. S02 ENHANCE/Henke2003 is a double-blind ITT trial report with351 participants, epoetin beta180/placebo171. It is separate from DAHANCA's darbepoetin formulation and denominators. Survival RR retains its original name/direction, and historical registration-era absence wording is not changed into new verification of registration absence. Report/material slots are not unique clinical trial, participant or independent-replication totals; clinical totals remain unrecorded. S03 RTOG99-03 links initial/long-term reports of the same148-participant epoetin alfa randomized trial in one existing citation. PMID17716826 and25670542 are preserved, and the URL points to long-term report25670542. Two reports, three-/five-year/OS outcomes and arms are not added as new independent trials or participants. Report/material slots are not unique clinical trial, participant or independent-replication totals; clinical totals remain unrecorded. S04 Cochrane/Bohlius2009 is a5RCT1,397-participant review. Inclusion/overlap with individual DAHANCA/ENHANCE/RTOG reports remains unverified; the review is not a new independent RCT. Review, individual-trial and sibling-sheet participants/trials are not summed. Report/material slots are not unique clinical trial, participant or independent-replication totals; clinical totals remain unrecorded. S05 refers to account2925 through an existing cross-citation absent from the evidence list, with another indication/endpoint: preterm-infant reduced transfusions, B72. That account/trial was not read in this production scope. It is not made into a direct head-and-neck cancer survival trial, independent replication or opposite effect. Report/material slots are not unique clinical trial, participant or independent-replication totals; clinical totals remain unrecorded.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Stored summary	Stored file	Stored summary	Summary read	Only the stored JSON summary and bibliography were used for production. This does not constitute external verification or completed content review.
External paper	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.
Registration material	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.
Protocol	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.
Statistical analysis plan	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.
Funding, product-support and COI material	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.
External FDA label	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.

S02 · Henke M et al. 2003 ENHANCE

PubMed

Material type: Multicenter randomized double-blind placebo-controlled trial
Materials actually read: Summary read; external material unread
Findings recorded in the stored summary: Adjusted RR1.62 (95% CI1.22~2.14), P=.0008; survival RR1.39 (1.05~1.84). Survival RR retains its original name; it is not changed into HR, death HR or absolute survival, and no reciprocal, new effect or denominator is calculated.
Record level: Outcome wording in the stored summary
Study overlap and independent replication: S01 DAHANCA10/Overgaard2018 is an open-label randomized phase3 report with planned600, randomized522 and evaluable513 (254/259). Primary locoregional failure, EFS, disease-specific death and overall death are separate. The same report, arms, people, endpoints or sibling sheets are not counted as new independent trials or participants. Report/material slots are not unique clinical trial, participant or independent-replication totals; clinical totals remain unrecorded. S02 ENHANCE/Henke2003 is a double-blind ITT trial report with351 participants, epoetin beta180/placebo171. It is separate from DAHANCA's darbepoetin formulation and denominators. Survival RR retains its original name/direction, and historical registration-era absence wording is not changed into new verification of registration absence. Report/material slots are not unique clinical trial, participant or independent-replication totals; clinical totals remain unrecorded. S03 RTOG99-03 links initial/long-term reports of the same148-participant epoetin alfa randomized trial in one existing citation. PMID17716826 and25670542 are preserved, and the URL points to long-term report25670542. Two reports, three-/five-year/OS outcomes and arms are not added as new independent trials or participants. Report/material slots are not unique clinical trial, participant or independent-replication totals; clinical totals remain unrecorded. S04 Cochrane/Bohlius2009 is a5RCT1,397-participant review. Inclusion/overlap with individual DAHANCA/ENHANCE/RTOG reports remains unverified; the review is not a new independent RCT. Review, individual-trial and sibling-sheet participants/trials are not summed. Report/material slots are not unique clinical trial, participant or independent-replication totals; clinical totals remain unrecorded. S05 refers to account2925 through an existing cross-citation absent from the evidence list, with another indication/endpoint: preterm-infant reduced transfusions, B72. That account/trial was not read in this production scope. It is not made into a direct head-and-neck cancer survival trial, independent replication or opposite effect. Report/material slots are not unique clinical trial, participant or independent-replication totals; clinical totals remain unrecorded.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Stored summary	Stored file	Stored summary	Summary read	Only the stored JSON summary and bibliography were used for production. This does not constitute external verification or completed content review.
External paper	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.
Registration material	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.
Protocol	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.
Statistical analysis plan	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.
Funding, product-support and COI material	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.

S03 · Machtay M et al. RTOG 99-03 and long-term follow-up

PubMed

Material type: Reports of the same multicenter randomized phase 3 trial
Materials actually read: Summary read; external material unread
Findings recorded in the stored summary: Three-year failure44% versus36%, P=.56; five-year46.2% versus39.4%, P=.42; OS36.9% versus38.2%, P=.54. Locoregional-failure timepoints and OS are separate. Absent original OS timepoint, CI or denominator values are not filled, and no new significance, difference or sum is produced.
Record level: Outcome wording in the stored summary
Study overlap and independent replication: S01 DAHANCA10/Overgaard2018 is an open-label randomized phase3 report with planned600, randomized522 and evaluable513 (254/259). Primary locoregional failure, EFS, disease-specific death and overall death are separate. The same report, arms, people, endpoints or sibling sheets are not counted as new independent trials or participants. Report/material slots are not unique clinical trial, participant or independent-replication totals; clinical totals remain unrecorded. S02 ENHANCE/Henke2003 is a double-blind ITT trial report with351 participants, epoetin beta180/placebo171. It is separate from DAHANCA's darbepoetin formulation and denominators. Survival RR retains its original name/direction, and historical registration-era absence wording is not changed into new verification of registration absence. Report/material slots are not unique clinical trial, participant or independent-replication totals; clinical totals remain unrecorded. S03 RTOG99-03 links initial/long-term reports of the same148-participant epoetin alfa randomized trial in one existing citation. PMID17716826 and25670542 are preserved, and the URL points to long-term report25670542. Two reports, three-/five-year/OS outcomes and arms are not added as new independent trials or participants. Report/material slots are not unique clinical trial, participant or independent-replication totals; clinical totals remain unrecorded. S04 Cochrane/Bohlius2009 is a5RCT1,397-participant review. Inclusion/overlap with individual DAHANCA/ENHANCE/RTOG reports remains unverified; the review is not a new independent RCT. Review, individual-trial and sibling-sheet participants/trials are not summed. Report/material slots are not unique clinical trial, participant or independent-replication totals; clinical totals remain unrecorded. S05 refers to account2925 through an existing cross-citation absent from the evidence list, with another indication/endpoint: preterm-infant reduced transfusions, B72. That account/trial was not read in this production scope. It is not made into a direct head-and-neck cancer survival trial, independent replication or opposite effect. Report/material slots are not unique clinical trial, participant or independent-replication totals; clinical totals remain unrecorded.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Stored summary	Stored file	Stored summary	Summary read	Only the stored JSON summary and bibliography were used for production. This does not constitute external verification or completed content review.
External paper	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.
Registration material	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.
Protocol	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.
Statistical analysis plan	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.
Funding, product-support and COI material	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.
External initial paper	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.

S04 · Bohlius J et al. 2009 systematic review

PubMed

Material type: Systematic review and meta-analysis of5 randomized trials
Materials actually read: Summary read; external material unread
Findings recorded in the stored summary: OS Peto OR0.73 (95% CI0.58~0.91), locoregional PFS OR0.63 (0.49~0.80): radiotherapy+EPO is worse. Peto OR/OR names and the original comparison direction are preserved. No reciprocal, HR, absolute risk or new pooled value is produced; the review's own funding/COI remain unverified.
Record level: Outcome wording in the stored summary
Study overlap and independent replication: S01 DAHANCA10/Overgaard2018 is an open-label randomized phase3 report with planned600, randomized522 and evaluable513 (254/259). Primary locoregional failure, EFS, disease-specific death and overall death are separate. The same report, arms, people, endpoints or sibling sheets are not counted as new independent trials or participants. Report/material slots are not unique clinical trial, participant or independent-replication totals; clinical totals remain unrecorded. S02 ENHANCE/Henke2003 is a double-blind ITT trial report with351 participants, epoetin beta180/placebo171. It is separate from DAHANCA's darbepoetin formulation and denominators. Survival RR retains its original name/direction, and historical registration-era absence wording is not changed into new verification of registration absence. Report/material slots are not unique clinical trial, participant or independent-replication totals; clinical totals remain unrecorded. S03 RTOG99-03 links initial/long-term reports of the same148-participant epoetin alfa randomized trial in one existing citation. PMID17716826 and25670542 are preserved, and the URL points to long-term report25670542. Two reports, three-/five-year/OS outcomes and arms are not added as new independent trials or participants. Report/material slots are not unique clinical trial, participant or independent-replication totals; clinical totals remain unrecorded. S04 Cochrane/Bohlius2009 is a5RCT1,397-participant review. Inclusion/overlap with individual DAHANCA/ENHANCE/RTOG reports remains unverified; the review is not a new independent RCT. Review, individual-trial and sibling-sheet participants/trials are not summed. Report/material slots are not unique clinical trial, participant or independent-replication totals; clinical totals remain unrecorded. S05 refers to account2925 through an existing cross-citation absent from the evidence list, with another indication/endpoint: preterm-infant reduced transfusions, B72. That account/trial was not read in this production scope. It is not made into a direct head-and-neck cancer survival trial, independent replication or opposite effect. Report/material slots are not unique clinical trial, participant or independent-replication totals; clinical totals remain unrecorded.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Stored summary	Stored file	Stored summary	Summary read	Only the stored JSON summary and bibliography were used for production. This does not constitute external verification or completed content review.
External paper	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.
Registration material	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.
Protocol	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.
Statistical analysis plan	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.
Funding, product-support and COI material	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.

S05 · Verdict2925 on reduced red-cell transfusions in very-low-birth-weight preterm infants has grade B,72 points.

Official source

Material type: Citation-only report; no row in the original review summary's evidence list
Materials actually read: Summary read; external material unread
Findings recorded in the stored summary: Even for the same drug, reduced transfusions in preterm infants concern a different indication and endpoint. They are not transferred into a direct effect for the selected survival question or a new independent-trial count.
Record level: Outcome wording in the stored summary
Study overlap and independent replication: S01 DAHANCA10/Overgaard2018 is an open-label randomized phase3 report with planned600, randomized522 and evaluable513 (254/259). Primary locoregional failure, EFS, disease-specific death and overall death are separate. The same report, arms, people, endpoints or sibling sheets are not counted as new independent trials or participants. Report/material slots are not unique clinical trial, participant or independent-replication totals; clinical totals remain unrecorded. S02 ENHANCE/Henke2003 is a double-blind ITT trial report with351 participants, epoetin beta180/placebo171. It is separate from DAHANCA's darbepoetin formulation and denominators. Survival RR retains its original name/direction, and historical registration-era absence wording is not changed into new verification of registration absence. Report/material slots are not unique clinical trial, participant or independent-replication totals; clinical totals remain unrecorded. S03 RTOG99-03 links initial/long-term reports of the same148-participant epoetin alfa randomized trial in one existing citation. PMID17716826 and25670542 are preserved, and the URL points to long-term report25670542. Two reports, three-/five-year/OS outcomes and arms are not added as new independent trials or participants. Report/material slots are not unique clinical trial, participant or independent-replication totals; clinical totals remain unrecorded. S04 Cochrane/Bohlius2009 is a5RCT1,397-participant review. Inclusion/overlap with individual DAHANCA/ENHANCE/RTOG reports remains unverified; the review is not a new independent RCT. Review, individual-trial and sibling-sheet participants/trials are not summed. Report/material slots are not unique clinical trial, participant or independent-replication totals; clinical totals remain unrecorded. S05 refers to account2925 through an existing cross-citation absent from the evidence list, with another indication/endpoint: preterm-infant reduced transfusions, B72. That account/trial was not read in this production scope. It is not made into a direct head-and-neck cancer survival trial, independent replication or opposite effect. Report/material slots are not unique clinical trial, participant or independent-replication totals; clinical totals remain unrecorded.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Stored summary	Stored file	Stored summary	Summary read	Only the stored JSON summary and bibliography were used for production. This does not constitute external verification or completed content review.
External manuscript	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.

Report counts versus independent study counts

S01 DAHANCA10/Overgaard2018 is an open-label randomized phase3 report with planned600, randomized522 and evaluable513 (254/259). Primary locoregional failure, EFS, disease-specific death and overall death are separate. The same report, arms, people, endpoints or sibling sheets are not counted as new independent trials or participants. Report/material slots are not unique clinical trial, participant or independent-replication totals; clinical totals remain unrecorded. S02 ENHANCE/Henke2003 is a double-blind ITT trial report with351 participants, epoetin beta180/placebo171. It is separate from DAHANCA's darbepoetin formulation and denominators. Survival RR retains its original name/direction, and historical registration-era absence wording is not changed into new verification of registration absence. Report/material slots are not unique clinical trial, participant or independent-replication totals; clinical totals remain unrecorded. S03 RTOG99-03 links initial/long-term reports of the same148-participant epoetin alfa randomized trial in one existing citation. PMID17716826 and25670542 are preserved, and the URL points to long-term report25670542. Two reports, three-/five-year/OS outcomes and arms are not added as new independent trials or participants. Report/material slots are not unique clinical trial, participant or independent-replication totals; clinical totals remain unrecorded. S04 Cochrane/Bohlius2009 is a5RCT1,397-participant review. Inclusion/overlap with individual DAHANCA/ENHANCE/RTOG reports remains unverified; the review is not a new independent RCT. Review, individual-trial and sibling-sheet participants/trials are not summed. Report/material slots are not unique clinical trial, participant or independent-replication totals; clinical totals remain unrecorded. S05 refers to account2925 through an existing cross-citation absent from the evidence list, with another indication/endpoint: preterm-infant reduced transfusions, B72. That account/trial was not read in this production scope. It is not made into a direct head-and-neck cancer survival trial, independent replication or opposite effect. Report/material slots are not unique clinical trial, participant or independent-replication totals; clinical totals remain unrecorded.

Review criteria

Version 1.0 · Criteria record date 2026-10-06. These are Chamgap's own application conditions, informed by the referenced methods. They do not constitute official assessment-tool certification or a new efficacy score.

N01 · Does the selected question concern improved survival or the parent tumor-control question?

Required materials and conditions: Preserve the survival subclaim, grade and note separately from the parent tumor-control claim, score and axes
Conditions for verification: The corresponding original materials and analysis scope must be available, with unverified matters distinguishable, for: Preserve the survival subclaim, grade and note separately from the parent tumor-control claim, score and axes. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This production condition links required and currently available materials for the selected question by distinguishing: Preserve the survival subclaim, grade and note separately from the parent tumor-control claim, score and axes.
Referenced methods: M03 §3.1, §3.2.1–3.2.4 principles for clarifying questions; Detailed separation rules are a custom design; M03 §3.2.4, M15 §15.3.1–15.3.3; Question-specific outcome adaptation is a custom design

N02 · What events and directions do the survival measures represent?

Required materials and conditions: Exact names and directions of death, survival, event-free survival and tumor control
Conditions for verification: The corresponding original materials and analysis scope must be available, with unverified matters distinguishable, for: Exact names and directions of death, survival, event-free survival and tumor control. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This production condition links required and currently available materials for the selected question by distinguishing: Exact names and directions of death, survival, event-free survival and tumor control.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; Question-specific outcome adaptation is a custom design; M08 §8.2.2, M15 §15.3.1; Custom application; M03 §3.2.4; Custom extension boundary

N03 · What population, study exposure and comparator did DAHANCA10 use?

Required materials and conditions: Actual cancer/anemia and radiotherapy population and the two arms' historical study conditions
Conditions for verification: The corresponding original materials and analysis scope must be available, with unverified matters distinguishable, for: Actual cancer/anemia and radiotherapy population and the two arms' historical study conditions. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This production condition links required and currently available materials for the selected question by distinguishing: Actual cancer/anemia and radiotherapy population and the two arms' historical study conditions.
Referenced methods: M03 §3.2.1; Detailed population conditions are a custom design; M03 §3.2.2–3.2.3; Reverse-direction labeling and test adaptation are a custom design; M08 §8.1–8.2.3; Custom application; M03 §3.2.3, M08 §8.2.2–8.2.3; Custom application

N04 · How do DAHANCA10 planned, randomized and evaluable denominators differ?

Required materials and conditions: Roles of planned600, randomized522, evaluable513 and254/259
Conditions for verification: The corresponding original materials and analysis scope must be available, with unverified matters distinguishable, for: Roles of planned600, randomized522, evaluable513 and254/259. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This production condition links required and currently available materials for the selected question by distinguishing: Roles of planned600, randomized522, evaluable513 and254/259.
Referenced methods: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptation is our own design; M08 §8.2.2, M15 §15.3.1; own application; M19 §19.1.2–19.2.4, M04 §4.6.3; own application

N05 · What plan and criteria governed interim stopping?

Required materials and conditions: Prespecified interim analysis, inferiority stopping threshold and follow-up plan
Conditions for verification: The corresponding original materials and analysis scope must be available, with unverified matters distinguishable, for: Prespecified interim analysis, inferiority stopping threshold and follow-up plan. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This production condition links required and currently available materials for the selected question by distinguishing: Prespecified interim analysis, inferiority stopping threshold and follow-up plan.
Referenced methods: M08 Table 8.2.a, M04 §4.6.3; Custom application; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; Design-specific adaptation is a custom design; M15 §15.3.1–15.3.3; Custom application

N06 · What is the hierarchy of the primary tumor-failure endpoint and selected survival outcomes?

Required materials and conditions: Primary endpoint, secondary survival outcomes, prespecified analysis hierarchy and multiplicity
Conditions for verification: The corresponding original materials and analysis scope must be available, with unverified matters distinguishable, for: Primary endpoint, secondary survival outcomes, prespecified analysis hierarchy and multiplicity. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This production condition links required and currently available materials for the selected question by distinguishing: Primary endpoint, secondary survival outcomes, prespecified analysis hierarchy and multiplicity.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; Question-specific outcome adaptation is a custom design; M08 Table 8.2.a, M04 §4.6.3; Custom application; M03 §3.2.4; Custom extension boundary

N07 · What analysis produced the DAHANCA10 disease-specific death result?

Required materials and conditions: Cause-of-death definition, denominator, time, HR/CI and handling of competing events
Conditions for verification: The corresponding original materials and analysis scope must be available, with unverified matters distinguishable, for: Cause-of-death definition, denominator, time, HR/CI and handling of competing events. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This production condition links required and currently available materials for the selected question by distinguishing: Cause-of-death definition, denominator, time, HR/CI and handling of competing events.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; Question-specific outcome adaptation is a custom design; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; Design-specific adaptation is a custom design; M08 §8.2.2, M15 §15.3.1; Custom application; M15 §15.3.1–15.3.3; Custom application; M19 §19.1.2–19.2.4; Detailed discrimination is a custom design

N08 · What analysis produced the DAHANCA10 overall-death result?

Required materials and conditions: Overall-death HR/CI, events/people, follow-up duration and analysis population
Conditions for verification: The corresponding original materials and analysis scope must be available, with unverified matters distinguishable, for: Overall-death HR/CI, events/people, follow-up duration and analysis population. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This production condition links required and currently available materials for the selected question by distinguishing: Overall-death HR/CI, events/people, follow-up duration and analysis population.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; Question-specific outcome adaptation is a custom design; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; Design-specific adaptation is a custom design; M08 §8.2.2, M15 §15.3.1; Custom application; M15 §15.3.1–15.3.3; Custom application; M19 §19.2 design-specific harm questions; Details of temporal relationships are a custom design

N09 · Can EFS be substituted for survival or cancer-specific death?

Required materials and conditions: Link event-free survival event composition, hierarchy and analysis separately
Conditions for verification: The corresponding original materials and analysis scope must be available, with unverified matters distinguishable, for: Link event-free survival event composition, hierarchy and analysis separately. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This production condition links required and currently available materials for the selected question by distinguishing: Link event-free survival event composition, hierarchy and analysis separately.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; Question-specific outcome adaptation is a custom design; M08 Table 8.2.a, M04 §4.6.3; Custom application; M03 §3.2.4; Custom extension boundary

N10 · May the five-year tumor-failure timepoint be assigned to every survival outcome?

Required materials and conditions: Actual endpoint-specific follow-up and distinction between absolute and time-to-event outcomes
Conditions for verification: The corresponding original materials and analysis scope must be available, with unverified matters distinguishable, for: Actual endpoint-specific follow-up and distinction between absolute and time-to-event outcomes. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This production condition links required and currently available materials for the selected question by distinguishing: Actual endpoint-specific follow-up and distinction between absolute and time-to-event outcomes.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; Question-specific outcome adaptation is a custom design; M03 §3.2.1–3.2.4; Dose, duration and effect-modification details are a custom design; M19 §19.1.2–19.2.4; Custom application

N11 · How might an open-label study and outcome assessment affect individual endpoints?

Required materials and conditions: Record allocation, open-label status, tumor assessment and death ascertainment separately
Conditions for verification: The corresponding original materials and analysis scope must be available, with unverified matters distinguishable, for: Record allocation, open-label status, tumor assessment and death ascertainment separately. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This production condition links required and currently available materials for the selected question by distinguishing: Record allocation, open-label status, tumor assessment and death ascertainment separately.
Referenced methods: M08 §8.1–8.2.3; Custom application; M08 Table 8.2.a, M03 §3.2.4; Custom application; M19 §19.1.2–19.2.4; Detailed discrimination is a custom design; M19 §19.1.2–19.2.4, M04 §4.6.3; Custom application

N12 · How were concurrent treatment and deviations reflected in survival estimates?

Required materials and conditions: Radiotherapy, concomitant treatment, crossover/adherence, ITT/PP and covariates
Conditions for verification: The corresponding original materials and analysis scope must be available, with unverified matters distinguishable, for: Radiotherapy, concomitant treatment, crossover/adherence, ITT/PP and covariates. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This production condition links required and currently available materials for the selected question by distinguishing: Radiotherapy, concomitant treatment, crossover/adherence, ITT/PP and covariates.
Referenced methods: M03 §3.2.3, M08 §8.2.2–8.2.3; internal application; M08 §8.2.2, M15 §15.3.1; internal application; design considerations in M19 §19.2.2–19.2.4; detailed confounding records are internally designed

N13 · Does successful hemoglobin correction imply improved survival?

Required materials and conditions: Distinguish anemia/hemoglobin surrogates from clinical survival events
Conditions for verification: The corresponding original materials and analysis scope must be available, with unverified matters distinguishable, for: Distinguish anemia/hemoglobin surrogates from clinical survival events. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This production condition links required and currently available materials for the selected question by distinguishing: Distinguish anemia/hemoglobin surrogates from clinical survival events.
Referenced methods: M03 §3.2.4; Custom extension boundary; M03 §3.2.2–3.2.3; Reverse-direction labeling and test adaptation are a custom design; M03 §3.2.4, M15 §15.3.1–15.3.3; Question-specific outcome adaptation is a custom design

N14 · How do the ENHANCE comparison and denominators differ from DAHANCA10?

Required materials and conditions: Scope of epoetin beta, blinded placebo comparison,351/180/171 and ITT
Conditions for verification: The corresponding original materials and analysis scope must be available, with unverified matters distinguishable, for: Scope of epoetin beta, blinded placebo comparison,351/180/171 and ITT. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This production condition links required and currently available materials for the selected question by distinguishing: Scope of epoetin beta, blinded placebo comparison,351/180/171 and ITT.
Referenced methods: M03 §3.2.1; Detailed population conditions are a custom design; M03 §3.2.2–3.2.3; Reverse-direction labeling and test adaptation are a custom design; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; Design-specific adaptation is a custom design; M08 §8.1–8.2.3; Custom application; M04 §4.6.1–4.6.2, M15 §15.3.1; Custom application

N15 · What does ENHANCE survival RR1.39 mean?

Required materials and conditions: Original 'survival RR' coding, direction and CI, separate from the tumor primary endpoint
Conditions for verification: The corresponding original materials and analysis scope must be available, with unverified matters distinguishable, for: Original 'survival RR' coding, direction and CI, separate from the tumor primary endpoint. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This production condition links required and currently available materials for the selected question by distinguishing: Original 'survival RR' coding, direction and CI, separate from the tumor primary endpoint.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; Question-specific outcome adaptation is a custom design; M08 §8.2.2, M15 §15.3.1; Custom application; M15 §15.3.1–15.3.3; Custom application; M08 Table 8.2.a, M04 §4.6.3; Custom application

N16 · Do the initial and long-term RTOG99-03 reports concern the same trial?

Required materials and conditions: Relationship of original trial/follow-up reports,148 participants, bibliography and timepoints
Conditions for verification: The corresponding original materials and analysis scope must be available, with unverified matters distinguishable, for: Relationship of original trial/follow-up reports,148 participants, bibliography and timepoints. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This production condition links required and currently available materials for the selected question by distinguishing: Relationship of original trial/follow-up reports,148 participants, bibliography and timepoints.
Referenced methods: M04 §4.6.1–4.6.2 distinction between studies and reports; Cohort/outcome linkage is a custom application; M04 §4.5–4.6 principles for collecting/selecting materials; Separating access from reading and hyperlink specifications is a custom design; M04 §4.6.1–4.6.2, M15 §15.3.1; Custom application

N17 · What are the periods and effects for RTOG survival and tumor failure?

Required materials and conditions: OS, three-/five-year locoregional failure, original P values and limits of nonsignificance
Conditions for verification: The corresponding original materials and analysis scope must be available, with unverified matters distinguishable, for: OS, three-/five-year locoregional failure, original P values and limits of nonsignificance. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This production condition links required and currently available materials for the selected question by distinguishing: OS, three-/five-year locoregional failure, original P values and limits of nonsignificance.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; Question-specific outcome adaptation is a custom design; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; Design-specific adaptation is a custom design; M04 §4.6.3, M15 §15.3.1–15.3.3; Status separation is a custom design; M15 §15.3.1–15.3.3; Custom application; M03 §3.2.1–3.2.4; Dose, duration and effect-modification details are a custom design

N18 · What are the direction and analysis denominators of the Cochrane survival OR?

Required materials and conditions: Names/coding of5RCT1397 participants, OS Peto OR and other pooled endpoints
Conditions for verification: The corresponding original materials and analysis scope must be available, with unverified matters distinguishable, for: Names/coding of5RCT1397 participants, OS Peto OR and other pooled endpoints. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This production condition links required and currently available materials for the selected question by distinguishing: Names/coding of5RCT1397 participants, OS Peto OR and other pooled endpoints.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are internally designed; M08 §8.2.2, M15 §15.3.1; internal application; M15 §15.3.1–15.3.3; internal application

N19 · How much do the review and individual reports overlap?

Required materials and conditions: Cross-links between review-included trials/follow-up reports and the three individual trials
Conditions for verification: The corresponding original materials and analysis scope must be available, with unverified matters distinguishable, for: Cross-links between review-included trials/follow-up reports and the three individual trials. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This production condition links required and currently available materials for the selected question by distinguishing: Cross-links between review-included trials/follow-up reports and the three individual trials.
Referenced methods: Study/report distinction in M04 §4.6.1–4.6.2; Cohort/outcome linkage is Chamgap application; M04 §4.6.1–4.6.2 and M15 §15.3.1; Chamgap application

N20 · How do formulation, population and duration differences relate to the selected scope?

Required materials and conditions: Differences in ESA/arms/periods, denominators and analyses, with independence unverified
Conditions for verification: The corresponding original materials and analysis scope must be available, with unverified matters distinguishable, for: Differences in ESA/arms/periods, denominators and analyses, with independence unverified. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This production condition links required and currently available materials for the selected question by distinguishing: Differences in ESA/arms/periods, denominators and analyses, with independence unverified.
Referenced methods: M04 §4.6.1–4.6.2, M15 §15.3.1; Custom application; M04 §4.6.1–4.6.2 distinction between studies and reports; Cohort/outcome linkage is a custom application; CHAMGAP's own independence and attribution conditions. Official method sections in this pilot do not validate all details of this item

N21 · How do cancer-survival harm and other safety outcomes differ?

Required materials and conditions: Separate definitions and analysis scopes for death/cancer outcomes, SAE, cardiovascular events and radiation toxicity
Conditions for verification: The corresponding original materials and analysis scope must be available, with unverified matters distinguishable, for: Separate definitions and analysis scopes for death/cancer outcomes, SAE, cardiovascular events and radiation toxicity. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Supplementary
Application exceptions: Supplement gaps in safety/death materials for the selected survival question. Tumor control, hemoglobin correction or other adverse-event statements do not determine overall safety, harm incidence, drug choice/substitution or treatment guidance.
Why this condition is needed: This production condition links required and currently available materials for the selected question by distinguishing: Separate definitions and analysis scopes for death/cancer outcomes, SAE, cardiovascular events and radiation toxicity.
Referenced methods: M19 §19.1.2–19.2.4; Chamgap application; M19 §19.1.2–19.2.4; Detailed distinctions are Chamgap design; M19 §19.1.2–19.2.4; Chamgap application; Chamgap interpretation boundary. M19 principles are referenced; no official causality tool was run

N22 · Are death causes, missingness, vulnerable groups and long-term scope verified?

Required materials and conditions: Death ascertainment, cause, competing events, follow-up loss and vulnerable-group specifications
Conditions for verification: The corresponding original materials and analysis scope must be available, with unverified matters distinguishable, for: Death ascertainment, cause, competing events, follow-up loss and vulnerable-group specifications. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Supplementary
Application exceptions: Supplement gaps in safety/death materials for the selected survival question. Tumor control, hemoglobin correction or other adverse-event statements do not determine overall safety, harm incidence, drug choice/substitution or treatment guidance.
Why this condition is needed: This production condition links required and currently available materials for the selected question by distinguishing: Death ascertainment, cause, competing events, follow-up loss and vulnerable-group specifications.
Referenced methods: M19 §19.1.2–19.2.4; Detailed discrimination is a custom design; M19 §19.2 design-specific harm questions; Details of temporal relationships are a custom design; M19 §19.1.2–19.2.4, M04 §4.6.3; Custom application; M19 §19.1.2–19.2.4; Custom application

N23 · What is the scope of DAHANCA10 support and investigator roles?

Required materials and conditions: Distinguish cash, free products, quality-control costs, study/manuscript roles and COI
Conditions for verification: The corresponding original materials and analysis scope must be available, with unverified matters distinguishable, for: Distinguish cash, free products, quality-control costs, study/manuscript roles and COI. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This production condition links required and currently available materials for the selected question by distinguishing: Distinguish cash, free products, quality-control costs, study/manuscript roles and COI.
Referenced methods: Chamgap's own conditions for independence and attribution. The official methodological sections used in this example do not validate every detail of these items.

N24 · Do ENHANCE, RTOG and review support have the same meaning?

Required materials and conditions: Funding, products, employees and COI for each company/public/review source
Conditions for verification: The corresponding original materials and analysis scope must be available, with unverified matters distinguishable, for: Funding, products, employees and COI for each company/public/review source. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This production condition links required and currently available materials for the selected question by distinguishing: Funding, products, employees and COI for each company/public/review source.
Referenced methods: Chamgap's own conditions for independence and attribution. The official methodological sections used in this example do not validate every detail of these items.

N25 · How do registration wording, actual registration identity and plans differ?

Required materials and conditions: Preserve original registration wording/identifiers separately from unread status
Conditions for verification: The corresponding original materials and analysis scope must be available, with unverified matters distinguishable, for: Preserve original registration wording/identifiers separately from unread status. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This production condition links required and currently available materials for the selected question by distinguishing: Preserve original registration wording/identifiers separately from unread status.
Referenced methods: M04 §4.5–4.6 material collection/selection principles; acquisition/reading separation and hyperlink specifications are internally designed; M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and internal design; M08 Table 8.2.a, M04 §4.6.3; internal application

N26 · Does the FDA warning account reflect actual reading of the original label?

Required materials and conditions: Separate the account's warning history from external FDA label/date/scope
Conditions for verification: The corresponding original materials and analysis scope must be available, with unverified matters distinguishable, for: Separate the account's warning history from external FDA label/date/scope. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Supplementary
Application exceptions: Supplement gaps in safety/death materials for the selected survival question. Tumor control, hemoglobin correction or other adverse-event statements do not determine overall safety, harm incidence, drug choice/substitution or treatment guidance.
Why this condition is needed: This production condition links required and currently available materials for the selected question by distinguishing: Separate the account's warning history from external FDA label/date/scope.
Referenced methods: M19 §19.1.2–19.2.4; Custom application; M04 §4.5–4.6 principles for collecting/selecting materials; Separating access from reading and hyperlink specifications is a custom design; M04 §4.5, §4.6.3; Limitations of the current material conversion follow the review scope and custom design; CHAMGAP's own interpretation boundary. M19 principles are referenced; no official causality tool was run

N27 · Does the reduced-transfusion account for another indication answer cancer survival?

Required materials and conditions: Distinguish the preterm-infant2925 citation from the selected head-and-neck cancer survival question
Conditions for verification: The corresponding original materials and analysis scope must be available, with unverified matters distinguishable, for: Distinguish the preterm-infant2925 citation from the selected head-and-neck cancer survival question. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This production condition links required and currently available materials for the selected question by distinguishing: Distinguish the preterm-infant2925 citation from the selected head-and-neck cancer survival question.
Referenced methods: M03 §3.1, §3.2.1–3.2.4 principles for clarifying questions; Detailed separation rules are a custom design; M04 §4.6.1–4.6.2 distinction between studies and reports; Cohort/outcome linkage is a custom application; M03 §3.2.4; Custom extension boundary

N28 · Can these findings be extended to CKD, other cancers or anemia conditions?

Required materials and conditions: Boundary between original head-and-neck cancer radiotherapy scope and other indications
Conditions for verification: The corresponding original materials and analysis scope must be available, with unverified matters distinguishable, for: Boundary between original head-and-neck cancer radiotherapy scope and other indications. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This production condition links required and currently available materials for the selected question by distinguishing: Boundary between original head-and-neck cancer radiotherapy scope and other indications.
Referenced methods: M03 §3.1, §3.2.1–3.2.4: principles for clarifying the question; detailed separation rules are Chamgap's own design; M03 §3.2.1; detailed population conditions are Chamgap's own design; M03 §3.2.2–3.2.3; reverse labeling and test adaptations are Chamgap's own design; M03 §3.2.1–3.2.4; dose, duration and effect-modification details are Chamgap's own design

N29 · How are preserved summaries and actual external reading displayed?

Required materials and conditions: Access status of summaries, external originals, registration, protocol, SAP and COI
Conditions for verification: The corresponding original materials and analysis scope must be available, with unverified matters distinguishable, for: Access status of summaries, external originals, registration, protocol, SAP and COI. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This production condition links required and currently available materials for the selected question by distinguishing: Access status of summaries, external originals, registration, protocol, SAP and COI.
Referenced methods: M04 §4.5–4.6 material collection/selection principles; acquisition/reading separation and hyperlink specifications are internally designed; M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and internal design

N30 · How are original Korean/English text, reference date, empty values and correction history retained?

Required materials and conditions: Preserve original languages,2026-08-26, empty correction/deliberation values, false and unrecorded values
Conditions for verification: The corresponding original materials and analysis scope must be available, with unverified matters distinguishable, for: Preserve original languages,2026-08-26, empty correction/deliberation values, false and unrecorded values. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This production condition links required and currently available materials for the selected question by distinguishing: Preserve original languages,2026-08-26, empty correction/deliberation values, false and unrecorded values.
Referenced methods: M03 §3.1, §3.2.1–3.2.4 question-clarification principles; detailed separation rules are internally designed; M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and internal design

N31 · Are condition application, table production and completed content review separate events?

Required materials and conditions: Distinguish conditions saved first, freezing, separate application and existing content-review status
Conditions for verification: The corresponding original materials and analysis scope must be available, with unverified matters distinguishable, for: Distinguish conditions saved first, freezing, separate application and existing content-review status. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This production condition links required and currently available materials for the selected question by distinguishing: Distinguish conditions saved first, freezing, separate application and existing content-review status.
Referenced methods: M04 §4.5–4.6 material collection/selection principles; acquisition/reading separation and hyperlink specifications are internally designed; M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and internal design

Referenced methods and the sections actually reviewed

M03 · Cochrane Handbook 6.5 (2024), chapter updated 2023-08

Official methodology · §3.1, §3.2.1–3.2.3, MECIR C5/C7/C13

Referenced principle: Clearly record the question, eligibility conditions and reasons for changes, and distinguish variations in interventions.
Extent of review: Preserved method HTML copies; no current method-content re-review or official tool execution

M04 · Cochrane Handbook 6.5.1 (2025), chapter updated 2025-03

Official methodology · §4.5, §4.6.1–4.6.3, MECIR C42

Referenced principle: Distinguish studies from reports and link them; do not omit a study solely because results are unreported.
Extent of review: Preserved method HTML copies; no current method-content re-review or official tool execution

M08 · Cochrane Handbook 6.5 (2024), chapter updated 2019-10

Official methodology · §8.1–8.2.3, Table 8.2.a

Referenced principle: Define the outcome and effect of interest, then examine randomization, deviations, missing data, measurement and selective reporting.
Extent of review: Preserved method HTML copies; no current method-content re-review or official tool execution

M15 · Cochrane Handbook 6.5 (2024), chapter updated 2023-08

Official methodology · §15.2.4, §15.3.1–15.3.3

Referenced principle: Distinguish effect estimates, intervals, importance and applicability. Sample size alone does not determine precision.
Extent of review: Preserved method HTML copies; no current method-content re-review or official tool execution

M19 · Cochrane Handbook 6.5 (2024), chapter updated 2019-10

Official methodology · §19.1.2, §19.2.1–19.2.4

Referenced principle: Harm questions may require different designs, populations and follow-up from efficacy questions. Case reports do not establish incidence rates.
Extent of review: Preserved method HTML copies; no current method-content re-review or official tool execution

What the statuses mean

Met: Status for necessary evidence confirmed after existing content review. No completion is declared in the current presentation.
Partly verified: Some information in the stored summary is linked into the table. External comparison/content review is not complete.
Unverified: The article leaves this unverified, or required material is absent from the current stored summary. This is distinct from zero, absence or safety.
Review incomplete: Existing content review remains incomplete.
Not reported: Not reported within the stored material actually read; not extended to the entire primary paper.
Inaccessible: Means an actual access failure. Access not attempted here is not assigned this state.
Not applicable: Not used as a substitute for an evidence gap.
Conflicting data: Requires an observed disagreement under the same comparison criteria; not automatically judged in this production.
Insufficient evidence for the conditions: Marks a gap in additional material required by the selected conditions; not a new efficacy grade.

Change history

2026-10-11 · Public page/material version 1.0

A public view and materials were prepared from the existing31 items. No new clinical search, verification-status change or scoring was performed.

The stored-material review date (Not recorded) and original evidence cut-off (2026-08-26) were retained unchanged.

Researcher downloads

These materials provide the same evidence, scope and verification status as this page.

View all item details

N01 · Does the selected question concern improved survival or the parent tumor-control question?

Current findings: The selected question is 'Improved survival', with original grade F and a note that disease-specific and overall death both significantly favored harm. The parent asks about improved locoregional tumor control and has F12, Warning and original assessment axes. The selected record has no score, status or axes.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the corresponding preserved-summary information was recorded; detailed original materials remain unread and existing content review is incomplete. The subclaim originally has no score, status or axes, and no new survival verdict was made. Existing content review remains incomplete.
Reason for missing information: The subclaim originally has no score, status or axes, and no new survival verdict was made.
Required materials and conditions: Preserve the survival subclaim, grade and note separately from the parent tumor-control claim, score and axes
Materials to obtain first: New subclaim materials or user correction comments
Further research: Proposal: Track survival and tumor-control materials separately; the record includes no new search, calculation or trial.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: The corresponding original materials and analysis scope must be available, with unverified matters distinguishable, for: Preserve the survival subclaim, grade and note separately from the parent tumor-control claim, score and axes. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This production condition links required and currently available materials for the selected question by distinguishing: Preserve the survival subclaim, grade and note separately from the parent tumor-control claim, score and axes.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.1, §3.2.1–3.2.4 principles for clarifying questions; Detailed separation rules are a custom design; M03 §3.2.4, M15 §15.3.1–15.3.3; Question-specific outcome adaptation is a custom design

Related sources S01 S02 S03 S04

N02 · What events and directions do the survival measures represent?

Current findings: The original account describes harm for DAHANCA10 disease-specific death, HR1.43 (95% CI1.08~1.90), and overall death, HR1.30 (1.02~1.64). EFS HR1.36 (1.09~1.69) and locoregional failure HR1.53 (1.16~2.02) are different outcomes. ENHANCE 'survival RR1.39' and the review's OS Peto OR0.73 retain their separate original names and directions.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the corresponding preserved-summary information was recorded; detailed original materials remain unread and existing content review is incomplete. Exact death/survival event coding and some estimator and analysis definitions cannot be fully verified from the summary. Existing content review remains incomplete.
Reason for missing information: Exact death/survival event coding and some estimator and analysis definitions cannot be fully verified from the summary.
Required materials and conditions: Exact names and directions of death, survival, event-free survival and tumor control
Materials to obtain first: Outcome definitions, original analysis tables and SAP
Further research: Proposal: Link endpoint-specific event coding and comparison directions; the record includes no new search, calculation or trial.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: The corresponding original materials and analysis scope must be available, with unverified matters distinguishable, for: Exact names and directions of death, survival, event-free survival and tumor control. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This production condition links required and currently available materials for the selected question by distinguishing: Exact names and directions of death, survival, event-free survival and tumor control.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; Question-specific outcome adaptation is a custom design; M08 §8.2.2, M15 §15.3.1; Custom application; M03 §3.2.4; Custom extension boundary

Related sources S01 S02 S04

N03 · What population, study exposure and comparator did DAHANCA10 use?

Current findings: The summary describes DAHANCA10 as a multicenter open-label randomized phase 3 comparison of weekly darbepoetin during head-and-neck cancer radiotherapy with hemoglobin <14.0g/dL. This is historical trial exposure, not an instruction on drug choice, substitution or use.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the corresponding preserved-summary information was recorded; detailed original materials remain unread and existing content review is incomplete. Details of cancer site/stage, baseline anemia, concurrent treatment, exact control management and exposure stopping conditions remain unverified. Existing content review remains incomplete.
Reason for missing information: Details of cancer site/stage, baseline anemia, concurrent treatment, exact control management and exposure stopping conditions remain unverified.
Required materials and conditions: Actual cancer/anemia and radiotherapy population and the two arms' historical study conditions
Materials to obtain first: Eligibility/exclusion criteria, baseline tables and both arms' concurrent-treatment/exposure records
Further research: Proposal: Link survival materials by population and comparison conditions; the record includes no new search, calculation or trial.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: The corresponding original materials and analysis scope must be available, with unverified matters distinguishable, for: Actual cancer/anemia and radiotherapy population and the two arms' historical study conditions. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This production condition links required and currently available materials for the selected question by distinguishing: Actual cancer/anemia and radiotherapy population and the two arms' historical study conditions.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.2.1; Detailed population conditions are a custom design; M03 §3.2.2–3.2.3; Reverse-direction labeling and test adaptation are a custom design; M08 §8.1–8.2.3; Custom application; M03 §3.2.3, M08 §8.2.2–8.2.3; Custom application

Related sources S01

N04 · How do DAHANCA10 planned, randomized and evaluable denominators differ?

Current findings: The original denominators were planned600, stopping after522 randomized, and513 evaluable (254/259). The513 is not automatically assigned to every survival or safety analysis, and no missing-person counts or proportions are newly calculated.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the corresponding preserved-summary information was recorded; detailed original materials remain unread and existing content review is incomplete. Reasons for exclusion between randomized and evaluable groups, survival-specific ITT/follow-up denominators and arm-specific missingness remain unverified. Existing content review remains incomplete.
Reason for missing information: Reasons for exclusion between randomized and evaluable groups, survival-specific ITT/follow-up denominators and arm-specific missingness remain unverified.
Required materials and conditions: Roles of planned600, randomized522, evaluable513 and254/259
Materials to obtain first: Participant flowchart, survival analysis populations and exclusion/follow-up records
Further research: Proposal: Separate analysis populations and exclusion reasons by denominator; the record includes no new search, calculation or trial.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: The corresponding original materials and analysis scope must be available, with unverified matters distinguishable, for: Roles of planned600, randomized522, evaluable513 and254/259. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This production condition links required and currently available materials for the selected question by distinguishing: Roles of planned600, randomized522, evaluable513 and254/259.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptation is our own design; M08 §8.2.2, M15 §15.3.1; own application; M19 §19.1.2–19.2.4, M04 §4.6.3; own application

Related sources S01

N05 · What plan and criteria governed interim stopping?

Current findings: The original DAHANCA10 account reports stopping at522 after a planned interim analysis found inferiority in the experimental arm. Planned600, actual522 and evaluable513 have different roles; no new effect correction for early stopping is made.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the corresponding preserved-summary information was recorded; detailed original materials remain unread and existing content review is incomplete. Interim timing/threshold, alpha spending, committee decisions and survival follow-up after stopping remain unverified. Existing content review remains incomplete.
Reason for missing information: Interim timing/threshold, alpha spending, committee decisions and survival follow-up after stopping remain unverified.
Required materials and conditions: Prespecified interim analysis, inferiority stopping threshold and follow-up plan
Materials to obtain first: Interim analysis plan, committee/stopping records and final analysis plan
Further research: Proposal: Document the relationship between interim analysis and final survival outcomes; the record includes no new search, calculation or trial.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: The corresponding original materials and analysis scope must be available, with unverified matters distinguishable, for: Prespecified interim analysis, inferiority stopping threshold and follow-up plan. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This production condition links required and currently available materials for the selected question by distinguishing: Prespecified interim analysis, inferiority stopping threshold and follow-up plan.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M08 Table 8.2.a, M04 §4.6.3; Custom application; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; Design-specific adaptation is a custom design; M15 §15.3.1–15.3.3; Custom application

Related sources S01

N06 · What is the hierarchy of the primary tumor-failure endpoint and selected survival outcomes?

Current findings: DAHANCA10's primary endpoint was time to locoregional failure. Five-year cumulative locoregional failure47% versus34% and HR1.53 (1.16~2.02) retain their original scope. They are not relabeled as a survival primary endpoint or five-year overall-death incidence.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the corresponding preserved-summary information was recorded; detailed original materials remain unread and existing content review is incomplete. Prespecified hierarchy, multiplicity and individual analysis timepoints for EFS, disease-specific death and overall death remain unverified. Existing content review remains incomplete.
Reason for missing information: Prespecified hierarchy, multiplicity and individual analysis timepoints for EFS, disease-specific death and overall death remain unverified.
Required materials and conditions: Primary endpoint, secondary survival outcomes, prespecified analysis hierarchy and multiplicity
Materials to obtain first: Protocol, SAP and endpoint-specific results tables
Further research: Proposal: Link endpoint hierarchy and prespecified multiple-comparison plans; the record includes no new search, calculation or trial.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: The corresponding original materials and analysis scope must be available, with unverified matters distinguishable, for: Primary endpoint, secondary survival outcomes, prespecified analysis hierarchy and multiplicity. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This production condition links required and currently available materials for the selected question by distinguishing: Primary endpoint, secondary survival outcomes, prespecified analysis hierarchy and multiplicity.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; Question-specific outcome adaptation is a custom design; M08 Table 8.2.a, M04 §4.6.3; Custom application; M03 §3.2.4; Custom extension boundary

Related sources S01

N07 · What analysis produced the DAHANCA10 disease-specific death result?

Current findings: Disease-specific death HR1.43 (95% CI1.08~1.90) retains its original name and harm direction. It is not converted into an overall-death HR, survival proportion or absolute death rate.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the corresponding preserved-summary information was recorded; detailed original materials remain unread and existing content review is incomplete. Cause adjudication, competing-death handling, original event counts, denominators, follow-up time, original P value and model details remain unverified. Existing content review remains incomplete.
Reason for missing information: Cause adjudication, competing-death handling, original event counts, denominators, follow-up time, original P value and model details remain unverified.
Required materials and conditions: Cause-of-death definition, denominator, time, HR/CI and handling of competing events
Materials to obtain first: Disease-specific death results, cause adjudication/follow-up and analysis plan
Further research: Proposal: Link endpoint definitions and competing-event/survival-analysis materials; the record includes no new search, calculation or trial.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: The corresponding original materials and analysis scope must be available, with unverified matters distinguishable, for: Cause-of-death definition, denominator, time, HR/CI and handling of competing events. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This production condition links required and currently available materials for the selected question by distinguishing: Cause-of-death definition, denominator, time, HR/CI and handling of competing events.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; Question-specific outcome adaptation is a custom design; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; Design-specific adaptation is a custom design; M08 §8.2.2, M15 §15.3.1; Custom application; M15 §15.3.1–15.3.3; Custom application; M19 §19.1.2–19.2.4; Detailed discrimination is a custom design

Related sources S01

N08 · What analysis produced the DAHANCA10 overall-death result?

Current findings: Overall death HR1.30 (95% CI1.02~1.64) is recorded as in the preserved material. It is a separate endpoint from disease-specific death HR1.43 and is not reversed into support for improved survival.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the corresponding preserved-summary information was recorded; detailed original materials remain unread and existing content review is incomplete. Overall-death event counts, denominators, exact follow-up duration, censoring/missingness, model/covariates and original P value remain unverified. Existing content review remains incomplete.
Reason for missing information: Overall-death event counts, denominators, exact follow-up duration, censoring/missingness, model/covariates and original P value remain unverified.
Required materials and conditions: Overall-death HR/CI, events/people, follow-up duration and analysis population
Materials to obtain first: Overall-death results, follow-up/censoring materials and SAP
Further research: Proposal: Document overall-death follow-up and analysis in the randomized population; the record includes no new search, calculation or trial.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: The corresponding original materials and analysis scope must be available, with unverified matters distinguishable, for: Overall-death HR/CI, events/people, follow-up duration and analysis population. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This production condition links required and currently available materials for the selected question by distinguishing: Overall-death HR/CI, events/people, follow-up duration and analysis population.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; Question-specific outcome adaptation is a custom design; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; Design-specific adaptation is a custom design; M08 §8.2.2, M15 §15.3.1; Custom application; M15 §15.3.1–15.3.3; Custom application; M19 §19.2 design-specific harm questions; Details of temporal relationships are a custom design

Related sources S01

N09 · Can EFS be substituted for survival or cancer-specific death?

Current findings: DAHANCA10 EFS HR1.36 (1.09~1.69) is a separate event-free survival outcome in the original account. It is not merged with locoregional failure, disease-specific death or overall death, and no component events are invented.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the corresponding preserved-summary information was recorded; detailed original materials remain unread and existing content review is incomplete. Exact composite EFS components, first-event rule, denominator and timepoint remain unverified in the summary. Existing content review remains incomplete.
Reason for missing information: Exact composite EFS components, first-event rule, denominator and timepoint remain unverified in the summary.
Required materials and conditions: Link event-free survival event composition, hierarchy and analysis separately
Materials to obtain first: EFS definition, results table and prespecified plan
Further research: Proposal: Document the composite endpoint and its components separately; the record includes no new search, calculation or trial.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: The corresponding original materials and analysis scope must be available, with unverified matters distinguishable, for: Link event-free survival event composition, hierarchy and analysis separately. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This production condition links required and currently available materials for the selected question by distinguishing: Link event-free survival event composition, hierarchy and analysis separately.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; Question-specific outcome adaptation is a custom design; M08 Table 8.2.a, M04 §4.6.3; Custom application; M03 §3.2.4; Custom extension boundary

Related sources S01

N10 · May the five-year tumor-failure timepoint be assigned to every survival outcome?

Current findings: DAHANCA10's five-year timepoint belongs to cumulative locoregional failure47%/34%. It is not assigned arbitrarily to the disease-specific death, overall-death or EFS HRs.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the corresponding preserved-summary information was recorded; detailed original materials remain unread and existing content review is incomplete. Survival-HR-specific median follow-up, end time, censoring and period-specific risk remain unverified. Existing content review remains incomplete.
Reason for missing information: Survival-HR-specific median follow-up, end time, censoring and period-specific risk remain unverified.
Required materials and conditions: Actual endpoint-specific follow-up and distinction between absolute and time-to-event outcomes
Materials to obtain first: Follow-up periods/timepoints, survival curves and censoring tables for each survival endpoint
Further research: Proposal: Separate time scopes by endpoint in follow-up materials; the record includes no new search, calculation or trial.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: The corresponding original materials and analysis scope must be available, with unverified matters distinguishable, for: Actual endpoint-specific follow-up and distinction between absolute and time-to-event outcomes. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This production condition links required and currently available materials for the selected question by distinguishing: Actual endpoint-specific follow-up and distinction between absolute and time-to-event outcomes.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; Question-specific outcome adaptation is a custom design; M03 §3.2.1–3.2.4; Dose, duration and effect-modification details are a custom design; M19 §19.1.2–19.2.4; Custom application

Related sources S01

N11 · How might an open-label study and outcome assessment affect individual endpoints?

Current findings: The original account describes DAHANCA10 as an open-label randomized study without uniform central blinded imaging assessment. Tumor-control assessment and overall-death ascertainment are not assumed to share the same measurement error.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the corresponding preserved-summary information was recorded; detailed original materials remain unread and existing content review is incomplete. Allocation concealment, cause-of-death adjudication, death follow-up/missingness and blinding of survival ascertainment remain unverified. Existing content review remains incomplete.
Reason for missing information: Allocation concealment, cause-of-death adjudication, death follow-up/missingness and blinding of survival ascertainment remain unverified.
Required materials and conditions: Record allocation, open-label status, tumor assessment and death ascertainment separately
Materials to obtain first: Allocation procedures, endpoint assessment/follow-up instructions and original materials
Further research: Proposal: Link endpoint-specific measurement and missingness materials; the record includes no new search, calculation or trial.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: The corresponding original materials and analysis scope must be available, with unverified matters distinguishable, for: Record allocation, open-label status, tumor assessment and death ascertainment separately. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This production condition links required and currently available materials for the selected question by distinguishing: Record allocation, open-label status, tumor assessment and death ascertainment separately.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M08 §8.1–8.2.3; Custom application; M08 Table 8.2.a, M03 §3.2.4; Custom application; M19 §19.1.2–19.2.4; Detailed discrimination is a custom design; M19 §19.1.2–19.2.4, M04 §4.6.3; Custom application

Related sources S01

N12 · How were concurrent treatment and deviations reflected in survival estimates?

Current findings: The original account compares ESA anemia correction during radiotherapy and retains DAHANCA10's open-label randomized design. Details of study exposure, actual transfusion, additional ESA, radiotherapy/chemotherapy and deviations are not filled in.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the corresponding preserved-summary information was recorded; detailed original materials remain unread and existing content review is incomplete. Arm-specific actual exposure, concurrent treatment, crossover/adherence, adjustment variables and survival ITT/PP analysis specifications remain unverified. Existing content review remains incomplete.
Reason for missing information: Arm-specific actual exposure, concurrent treatment, crossover/adherence, adjustment variables and survival ITT/PP analysis specifications remain unverified.
Required materials and conditions: Radiotherapy, concomitant treatment, crossover/adherence, ITT/PP and covariates
Materials to obtain first: Both arms' actual treatment/deviations, crossover records and SAP
Further research: Proposal: Document concurrent treatment and comparison estimators; the record includes no new search, calculation or trial.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: The corresponding original materials and analysis scope must be available, with unverified matters distinguishable, for: Radiotherapy, concomitant treatment, crossover/adherence, ITT/PP and covariates. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This production condition links required and currently available materials for the selected question by distinguishing: Radiotherapy, concomitant treatment, crossover/adherence, ITT/PP and covariates.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.2.3, M08 §8.2.2–8.2.3; internal application; M08 §8.2.2, M15 §15.3.1; internal application; design considerations in M19 §19.2.2–19.2.4; detailed confounding records are internally designed

Related sources S01

N13 · Does successful hemoglobin correction imply improved survival?

Current findings: The parent advertising and interpretation text distinguishes anemia correction from survival/tumor control during cancer treatment. Hemoglobin correction itself is not transferred into survival benefit, and the selected record's death-harm note is preserved.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the corresponding preserved-summary information was recorded; detailed original materials remain unread and existing content review is incomplete. Trial-specific hemoglobin changes, reduced-transfusion values and prespecified mediation analyses relating these to survival remain unverified in this summary. Existing content review remains incomplete.
Reason for missing information: Trial-specific hemoglobin changes, reduced-transfusion values and prespecified mediation analyses relating these to survival remain unverified in this summary.
Required materials and conditions: Distinguish anemia/hemoglobin surrogates from clinical survival events
Materials to obtain first: Trial-specific hemoglobin/transfusion results and prespecified survival-related analyses
Further research: Proposal: Document surrogate measures and clinical events separately; the record includes no new search, calculation or trial.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: The corresponding original materials and analysis scope must be available, with unverified matters distinguishable, for: Distinguish anemia/hemoglobin surrogates from clinical survival events. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This production condition links required and currently available materials for the selected question by distinguishing: Distinguish anemia/hemoglobin surrogates from clinical survival events.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.2.4; Custom extension boundary; M03 §3.2.2–3.2.3; Reverse-direction labeling and test adaptation are a custom design; M03 §3.2.4, M15 §15.3.1–15.3.3; Question-specific outcome adaptation is a custom design

Related sources S01 S02 S03

N14 · How do the ENHANCE comparison and denominators differ from DAHANCA10?

Current findings: ENHANCE reports a multicenter randomized double-blind placebo comparison with351 participants, epoetin beta180/placebo171, and ITT. These are not treated as the same arms, formulation or522/513 denominators as DAHANCA10 darbepoetin.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the corresponding preserved-summary information was recorded; detailed original materials remain unread and existing content review is incomplete. Baseline conditions, exact dose/duration, survival-specific observation/censoring, concurrent treatment and analysis details remain unverified. Existing content review remains incomplete.
Reason for missing information: Baseline conditions, exact dose/duration, survival-specific observation/censoring, concurrent treatment and analysis details remain unverified.
Required materials and conditions: Scope of epoetin beta, blinded placebo comparison,351/180/171 and ITT
Materials to obtain first: ENHANCE protocol, participant flow and survival analysis tables
Further research: Proposal: Separate population, formulation and comparison differences; the record includes no new search, calculation or trial.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: The corresponding original materials and analysis scope must be available, with unverified matters distinguishable, for: Scope of epoetin beta, blinded placebo comparison,351/180/171 and ITT. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This production condition links required and currently available materials for the selected question by distinguishing: Scope of epoetin beta, blinded placebo comparison,351/180/171 and ITT.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.2.1; Detailed population conditions are a custom design; M03 §3.2.2–3.2.3; Reverse-direction labeling and test adaptation are a custom design; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; Design-specific adaptation is a custom design; M08 §8.1–8.2.3; Custom application; M04 §4.6.1–4.6.2, M15 §15.3.1; Custom application

Related sources S02

N15 · What does ENHANCE survival RR1.39 mean?

Current findings: ENHANCE reports a harm direction for survival RR1.39 (95% CI1.05~1.84). Its original primary locoregional progression-free survival adjusted RR1.62 (1.22~2.14), P=.0008, is separate. Survival RR is not renamed HR, death HR or absolute death rate, and no reciprocal is calculated.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the corresponding preserved-summary information was recorded; detailed original materials remain unread and existing content review is incomplete. Exact survival-RR event/control coding, time, model, denominator/events and original P value remain unverified. Existing content review remains incomplete.
Reason for missing information: Exact survival-RR event/control coding, time, model, denominator/events and original P value remain unverified.
Required materials and conditions: Original 'survival RR' coding, direction and CI, separate from the tumor primary endpoint
Materials to obtain first: ENHANCE original results, endpoint/model definitions and SAP
Further research: Proposal: Document the original estimator name and comparison direction; the record includes no new search, calculation or trial.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: The corresponding original materials and analysis scope must be available, with unverified matters distinguishable, for: Original 'survival RR' coding, direction and CI, separate from the tumor primary endpoint. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This production condition links required and currently available materials for the selected question by distinguishing: Original 'survival RR' coding, direction and CI, separate from the tumor primary endpoint.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; Question-specific outcome adaptation is a custom design; M08 §8.2.2, M15 §15.3.1; Custom application; M15 §15.3.1–15.3.3; Custom application; M08 Table 8.2.a, M04 §4.6.3; Custom application

Related sources S02

N16 · Do the initial and long-term RTOG99-03 reports concern the same trial?

Current findings: The initial and long-term RTOG99-03 reports are linked to the same148-participant randomized trial. The original citation contains PMID17716826 and25670542, with the URL pointing to the25670542 long-term report. The reports are not added as separate independent trials or new participants.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the corresponding preserved-summary information was recorded; detailed original materials remain unread and existing content review is incomplete. Exact participant flow, endpoint-specific follow-up and links between original bibliography and materials remain unread externally. Existing content review remains incomplete.
Reason for missing information: Exact participant flow, endpoint-specific follow-up and links between original bibliography and materials remain unread externally.
Required materials and conditions: Relationship of original trial/follow-up reports,148 participants, bibliography and timepoints
Materials to obtain first: Initial/long-term reports, trial registration and participant/outcome linkage tables
Further research: Proposal: Document time-specific reports from the same cohort; the record includes no new search, calculation or trial.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: The corresponding original materials and analysis scope must be available, with unverified matters distinguishable, for: Relationship of original trial/follow-up reports,148 participants, bibliography and timepoints. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This production condition links required and currently available materials for the selected question by distinguishing: Relationship of original trial/follow-up reports,148 participants, bibliography and timepoints.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M04 §4.6.1–4.6.2 distinction between studies and reports; Cohort/outcome linkage is a custom application; M04 §4.5–4.6 principles for collecting/selecting materials; Separating access from reading and hyperlink specifications is a custom design; M04 §4.6.1–4.6.2, M15 §15.3.1; Custom application

Related sources S03

N17 · What are the periods and effects for RTOG survival and tumor failure?

Current findings: RTOG99-03 reports three-year locoregional failure44% versus36%, P=.56, and five-year46.2% versus39.4%, P=.42. OS36.9% versus38.2%, P=.54, is a separate survival outcome. No exact OS period is invented, and nonsignificance is not treated as zero effect, equivalence or certified exclusion of an important survival benefit.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the corresponding preserved-summary information was recorded; detailed original materials remain unread and existing content review is incomplete. Exact OS timepoint, CI, events/denominators, censoring, power and estimation model remain unverified in the summary. Existing content review remains incomplete.
Reason for missing information: Exact OS timepoint, CI, events/denominators, censoring, power and estimation model remain unverified in the summary.
Required materials and conditions: OS, three-/five-year locoregional failure, original P values and limits of nonsignificance
Materials to obtain first: RTOG long-term survival tables, follow-up materials and prespecified plans
Further research: Proposal: Link time-specific tumor/survival outcomes and precision materials; the record includes no new search, calculation or trial.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: The corresponding original materials and analysis scope must be available, with unverified matters distinguishable, for: OS, three-/five-year locoregional failure, original P values and limits of nonsignificance. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This production condition links required and currently available materials for the selected question by distinguishing: OS, three-/five-year locoregional failure, original P values and limits of nonsignificance.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; Question-specific outcome adaptation is a custom design; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; Design-specific adaptation is a custom design; M04 §4.6.3, M15 §15.3.1–15.3.3; Status separation is a custom design; M15 §15.3.1–15.3.3; Custom application; M03 §3.2.1–3.2.4; Dose, duration and effect-modification details are a custom design

Related sources S03

N18 · What are the direction and analysis denominators of the Cochrane survival OR?

Current findings: The2009 Cochrane review preserves OS Peto OR0.73 (95% CI0.58~0.91) and locoregional progression-free survival OR0.63 (0.49~0.80), in the context of5RCTs and1,397 participants. The original account describes radiotherapy+EPO as worse than radiotherapy alone and OR<1 as favoring radiotherapy alone. No reciprocal, new HR or absolute effect is produced.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the corresponding preserved-summary information was recorded; detailed original materials remain unread and existing content review is incomplete. Endpoint-specific event coding, actual included denominators, models/weights, original P values and trial mapping remain unverified. Existing content review remains incomplete.
Reason for missing information: Endpoint-specific event coding, actual included denominators, models/weights, original P values and trial mapping remain unverified.
Required materials and conditions: Names/coding of5RCT1397 participants, OS Peto OR and other pooled endpoints
Materials to obtain first: Review results, forest plots, included trials/denominators and analysis definitions
Further research: Proposal: Document pooled-endpoint comparison directions and included denominators; the record includes no new search, calculation or trial.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: The corresponding original materials and analysis scope must be available, with unverified matters distinguishable, for: Names/coding of5RCT1397 participants, OS Peto OR and other pooled endpoints. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This production condition links required and currently available materials for the selected question by distinguishing: Names/coding of5RCT1397 participants, OS Peto OR and other pooled endpoints.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are internally designed; M08 §8.2.2, M15 §15.3.1; internal application; M15 §15.3.1–15.3.3; internal application

Related sources S04

N19 · How much do the review and individual reports overlap?

Current findings: DAHANCA10, ENHANCE, RTOG99-03 and the Cochrane5-trial1,397-participant review are distinguished at report, trial-family and synthesis levels. The review inclusion list and time-specific overlap remain unverified. The three reports are not added to the5 trials, and1397,522,351 and148 are not summed.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the corresponding preserved-summary information was recorded; detailed original materials remain unread and existing content review is incomplete. Included-trial lists, follow-up mappings, endpoint-specific overlap/exclusions and unique clinical totals remain unverified. Existing content review remains incomplete.
Reason for missing information: Included-trial lists, follow-up mappings, endpoint-specific overlap/exclusions and unique clinical totals remain unverified.
Required materials and conditions: Cross-links between review-included trials/follow-up reports and the three individual trials
Materials to obtain first: Review inclusion/exclusion tables and report↔trial↔population linkage tables
Further research: Proposal: Describe shared/overlapping relationships between synthesis and direct reports; the record includes no new search, calculation or trial.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: The corresponding original materials and analysis scope must be available, with unverified matters distinguishable, for: Cross-links between review-included trials/follow-up reports and the three individual trials. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This production condition links required and currently available materials for the selected question by distinguishing: Cross-links between review-included trials/follow-up reports and the three individual trials.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: Study/report distinction in M04 §4.6.1–4.6.2; Cohort/outcome linkage is Chamgap application; M04 §4.6.1–4.6.2 and M15 §15.3.1; Chamgap application

Related sources S01 S02 S03 S04

N20 · How do formulation, population and duration differences relate to the selected scope?

Current findings: DAHANCA10 open-label darbepoetin comparison, ENHANCE placebo-controlled epoetin beta, RTOG99-03 epoetin alfa conditions and the review's mixture are preserved separately. Original RX/I1 and historical investigator-independence statements are not inherited as current independent-replication certification.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the corresponding preserved-summary information was recorded; detailed original materials remain unread and existing content review is incomplete. Unique replication counts under the same selected conditions, formulation equivalence, arm-specific effect modification and review heterogeneity details remain unverified. Existing content review remains incomplete.
Reason for missing information: Unique replication counts under the same selected conditions, formulation equivalence, arm-specific effect modification and review heterogeneity details remain unverified.
Required materials and conditions: Differences in ESA/arms/periods, denominators and analyses, with independence unverified
Materials to obtain first: Trial-specific characteristics/endpoints, report families and heterogeneity materials
Further research: Proposal: Link replication/heterogeneity materials while separating different conditions; the record includes no new search, calculation or trial.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: The corresponding original materials and analysis scope must be available, with unverified matters distinguishable, for: Differences in ESA/arms/periods, denominators and analyses, with independence unverified. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This production condition links required and currently available materials for the selected question by distinguishing: Differences in ESA/arms/periods, denominators and analyses, with independence unverified.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M04 §4.6.1–4.6.2, M15 §15.3.1; Custom application; M04 §4.6.1–4.6.2 distinction between studies and reports; Cohort/outcome linkage is a custom application; CHAMGAP's own independence and attribution conditions. Official method sections in this pilot do not validate all details of this item

Related sources S01 S02 S03 S04

N21 · How do cancer-survival harm and other safety outcomes differ?

Current findings: Cancer-survival/tumor-control harm is central in the original account. The statement that DAHANCA10 found no excess serious adverse events, cardiovascular events or acute/late radiation toxicity is separate. Absence of other safety signals is not rewritten as overall safety or absence of cancer harm.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the corresponding preserved-summary information was recorded; detailed original materials remain unread and existing content review is incomplete. Definitions, ascertainment, events/denominators, exposure/follow-up, missingness and precision for individual safety outcomes remain unverified. Existing content review remains incomplete.
Reason for missing information: Definitions, ascertainment, events/denominators, exposure/follow-up, missingness and precision for individual safety outcomes remain unverified.
Required materials and conditions: Separate definitions and analysis scopes for death/cancer outcomes, SAE, cardiovascular events and radiation toxicity
Materials to obtain first: Trial-specific safety results, collection instructions and exposure/follow-up
Further research: Proposal: Separate cancer outcomes and other safety events; the record includes no new search, calculation or trial.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: The corresponding original materials and analysis scope must be available, with unverified matters distinguishable, for: Separate definitions and analysis scopes for death/cancer outcomes, SAE, cardiovascular events and radiation toxicity. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This production condition links required and currently available materials for the selected question by distinguishing: Separate definitions and analysis scopes for death/cancer outcomes, SAE, cardiovascular events and radiation toxicity.
Application exceptions: Supplement gaps in safety/death materials for the selected survival question. Tumor control, hemoglobin correction or other adverse-event statements do not determine overall safety, harm incidence, drug choice/substitution or treatment guidance.
Referenced methods: M19 §19.1.2–19.2.4; Chamgap application; M19 §19.1.2–19.2.4; Detailed distinctions are Chamgap design; M19 §19.1.2–19.2.4; Chamgap application; Chamgap interpretation boundary. M19 principles are referenced; no official causality tool was run

Related sources S01

N22 · Are death causes, missingness, vulnerable groups and long-term scope verified?

Current findings: The selected question preserves disease-specific and overall death separately and uses the original overall-death HR/CI. Long-term survival, vulnerable groups and cancer-site/stage results are not filled with values absent from the preserved materials.
Verification status: Unverified
Materials actually read: Summary read; external material unread
Why unverified: Currently required information remains unverified in the preserved summary. Cause adjudication, competing events, arm-specific follow-up loss, periods beyond follow-up and prespecified subgroups remain unverified. Existing content review remains incomplete.
Reason for missing information: Cause adjudication, competing events, arm-specific follow-up loss, periods beyond follow-up and prespecified subgroups remain unverified.
Required materials and conditions: Death ascertainment, cause, competing events, follow-up loss and vulnerable-group specifications
Materials to obtain first: Survival follow-up/cause-of-death materials and subgroup/long-term plans
Further research: Proposal: Separate time- and vulnerable-group-specific evidence gaps in follow-up materials; the record includes no new search, calculation or trial.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: The corresponding original materials and analysis scope must be available, with unverified matters distinguishable, for: Death ascertainment, cause, competing events, follow-up loss and vulnerable-group specifications. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This production condition links required and currently available materials for the selected question by distinguishing: Death ascertainment, cause, competing events, follow-up loss and vulnerable-group specifications.
Application exceptions: Supplement gaps in safety/death materials for the selected survival question. Tumor control, hemoglobin correction or other adverse-event statements do not determine overall safety, harm incidence, drug choice/substitution or treatment guidance.
Referenced methods: M19 §19.1.2–19.2.4; Detailed discrimination is a custom design; M19 §19.2 design-specific harm questions; Details of temporal relationships are a custom design; M19 §19.1.2–19.2.4, M04 §4.6.3; Custom application; M19 §19.1.2–19.2.4; Custom application

Related sources S01 S02 S03

N23 · What is the scope of DAHANCA10 support and investigator roles?

Current findings: The original account describes Danish Cancer Society and Amgen support, free Aranesp from Amgen and Amgen bearing most GCP/quality-control costs. Its investigator-driven statement, no Amgen role in design/conduct/collection/analysis, and an opportunity for manuscript comments without comments provided are preserved as history.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the corresponding preserved-summary information was recorded; detailed original materials remain unread and existing content review is incomplete. Support agreements, actual decision-making, employee authors, author-specific COI, other publication costs and original disclosures remain unread externally. Existing content review remains incomplete.
Reason for missing information: Support agreements, actual decision-making, employee authors, author-specific COI, other publication costs and original disclosures remain unread externally.
Required materials and conditions: Distinguish cash, free products, quality-control costs, study/manuscript roles and COI
Materials to obtain first: Support/product/quality-control agreements, original author/COI and contribution disclosures
Further research: Proposal: Separate types of support and study/manuscript roles; the record includes no new search, calculation or trial.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: The corresponding original materials and analysis scope must be available, with unverified matters distinguishable, for: Distinguish cash, free products, quality-control costs, study/manuscript roles and COI. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This production condition links required and currently available materials for the selected question by distinguishing: Distinguish cash, free products, quality-control costs, study/manuscript roles and COI.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: Chamgap's own conditions for independence and attribution. The official methodological sections used in this example do not validate every detail of these items.

Related sources S01

N24 · Do ENHANCE, RTOG and review support have the same meaning?

Current findings: ENHANCE F.Hoffmann-LaRoche and RTOG NCI/OrthoBiotech support are preserved separately. Mixed public/company support statements for the Cochrane review and included trials are not transferred into verification of the review's own funding or COI.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the corresponding preserved-summary information was recorded; detailed original materials remain unread and existing content review is incomplete. Free products, employee authors, actual roles and COI for each report, and the review's own funding/COI remain unverified. Existing content review remains incomplete.
Reason for missing information: Free products, employee authors, actual roles and COI for each report, and the review's own funding/COI remain unverified.
Required materials and conditions: Funding, products, employees and COI for each company/public/review source
Materials to obtain first: Report-specific original funding/product support, authors, contributions and COI materials, and review disclosures
Further research: Proposal: Link direct-trial and review support separately; the record includes no new search, calculation or trial.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: The corresponding original materials and analysis scope must be available, with unverified matters distinguishable, for: Funding, products, employees and COI for each company/public/review source. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This production condition links required and currently available materials for the selected question by distinguishing: Funding, products, employees and COI for each company/public/review source.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: Chamgap's own conditions for independence and attribution. The official methodological sections used in this example do not validate every detail of these items.

Related sources S02 S03 S04

N25 · How do registration wording, actual registration identity and plans differ?

Current findings: The DAHANCA10/ENHANCE statement 'predates registration systems, so none exists' is historical wording with actual identifiers unrecorded. RTOG's NCT00004917 retains only the original identifier. The review's 'not applicable' is not treated as certified absence of clinical registration.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the corresponding preserved-summary information was recorded; detailed original materials remain unread and existing content review is incomplete. Actual registration text, change history, prespecified endpoints/follow-up, protocol and SAP are unread, with no access attempt. Existing content review remains incomplete.
Reason for missing information: Actual registration text, change history, prespecified endpoints/follow-up, protocol and SAP are unread, with no access attempt.
Required materials and conditions: Preserve original registration wording/identifiers separately from unread status
Materials to obtain first: Registration or plan copies, or user-supplied materials
Further research: Proposal: Link registration/plan histories by report; the record includes no new search, calculation or trial.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: The corresponding original materials and analysis scope must be available, with unverified matters distinguishable, for: Preserve original registration wording/identifiers separately from unread status. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This production condition links required and currently available materials for the selected question by distinguishing: Preserve original registration wording/identifiers separately from unread status.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M04 §4.5–4.6 material collection/selection principles; acquisition/reading separation and hyperlink specifications are internally designed; M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and internal design; M08 Table 8.2.a, M04 §4.6.3; internal application

Related sources S01 S02 S03 S04

N26 · Does the FDA warning account reflect actual reading of the original label?

Current findings: The parent account contains an FDA warning that ESAs may shorten survival or increase tumor progression/recurrence in head-and-neck and other cancers. The FDA label remains unread in this work; no separate URL was provided in the preserved summary, so no address is invented.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the corresponding preserved-summary information was recorded; detailed original materials remain unread and existing content review is incomplete. Label version, actual warning text, indications/exceptions and update date remain unverified. Existing content review remains incomplete.
Reason for missing information: Label version, actual warning text, indications/exceptions and update date remain unverified.
Required materials and conditions: Separate the account's warning history from external FDA label/date/scope
Materials to obtain first: Original FDA label/warning version or user-provided materials
Further research: Proposal: Link the original warning account to version-specific sources; the record includes no new search, calculation or trial.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: The corresponding original materials and analysis scope must be available, with unverified matters distinguishable, for: Separate the account's warning history from external FDA label/date/scope. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This production condition links required and currently available materials for the selected question by distinguishing: Separate the account's warning history from external FDA label/date/scope.
Application exceptions: Supplement gaps in safety/death materials for the selected survival question. Tumor control, hemoglobin correction or other adverse-event statements do not determine overall safety, harm incidence, drug choice/substitution or treatment guidance.
Referenced methods: M19 §19.1.2–19.2.4; Custom application; M04 §4.5–4.6 principles for collecting/selecting materials; Separating access from reading and hyperlink specifications is a custom design; M04 §4.5, §4.6.3; Limitations of the current material conversion follow the review scope and custom design; CHAMGAP's own interpretation boundary. M19 principles are referenced; no official causality tool was run

Related sources S01

N27 · Does the reduced-transfusion account for another indication answer cancer survival?

Current findings: The contextual2925 citation refers to a B72 account of reduced red-cell transfusions in very-low-birth-weight preterm infants. That indication and transfusion endpoint differ from cancer survival here. The citation is not turned into a direct survival trial, new RCT or opposite survival effect.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the corresponding preserved-summary information was recorded; detailed original materials remain unread and existing content review is incomplete. That account's original text/trial and any direct link to these materials remain unread in this work. It is not substitute evidence for the selected survival question. Existing content review remains incomplete.
Reason for missing information: That account's original text/trial and any direct link to these materials remain unread in this work. It is not substitute evidence for the selected survival question.
Required materials and conditions: Distinguish the preterm-infant2925 citation from the selected head-and-neck cancer survival question
Materials to obtain first: Record indication/endpoint relationships if materials for the referenced account are provided
Further research: Proposal: Separate source relationships for different indications; the record includes no new search, calculation or trial.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: The corresponding original materials and analysis scope must be available, with unverified matters distinguishable, for: Distinguish the preterm-infant2925 citation from the selected head-and-neck cancer survival question. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This production condition links required and currently available materials for the selected question by distinguishing: Distinguish the preterm-infant2925 citation from the selected head-and-neck cancer survival question.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.1, §3.2.1–3.2.4 principles for clarifying questions; Detailed separation rules are a custom design; M04 §4.6.1–4.6.2 distinction between studies and reports; Cohort/outcome linkage is a custom application; M03 §3.2.4; Custom extension boundary

Related sources S05

N28 · Can these findings be extended to CKD, other cancers or anemia conditions?

Current findings: This sheet concerns survival with ESA anemia correction during head-and-neck cancer radiotherapy. Other anemia indications and preterm-infant transfusion context in the account are not transferred into head-and-neck cancer survival outcomes or extended into new effect/contraindication verdicts for every ESA indication.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the corresponding preserved-summary information was recorded; detailed original materials remain unread and existing content review is incomplete. Direct survival materials for other indications, anemia severity, target hemoglobin and treatment combinations are outside this production scope and remain unverified. Existing content review remains incomplete.
Reason for missing information: Direct survival materials for other indications, anemia severity, target hemoglobin and treatment combinations are outside this production scope and remain unverified.
Required materials and conditions: Boundary between original head-and-neck cancer radiotherapy scope and other indications
Materials to obtain first: Link separate indication-specific direct materials if provided
Further research: Proposal: Separate condition-specific questions and direct-material scope in follow-up materials; the record includes no new search, calculation or trial.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: The corresponding original materials and analysis scope must be available, with unverified matters distinguishable, for: Boundary between original head-and-neck cancer radiotherapy scope and other indications. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This production condition links required and currently available materials for the selected question by distinguishing: Boundary between original head-and-neck cancer radiotherapy scope and other indications.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.1, §3.2.1–3.2.4: principles for clarifying the question; detailed separation rules are Chamgap's own design; M03 §3.2.1; detailed population conditions are Chamgap's own design; M03 §3.2.2–3.2.3; reverse labeling and test adaptations are Chamgap's own design; M03 §3.2.1–3.2.4; dose, duration and effect-modification details are Chamgap's own design

Related sources S01 S02 S03 S05

N29 · How are preserved summaries and actual external reading displayed?

Current findings: The full preserved summary's Korean/English text, evidence, citations and subclaims were read for production and preserved. Each preserved JSON summary is shown as 'summary read'; external papers, registration, plans and support materials are 'unread'. Bibliography, URLs, registration numbers and historical review statements do not prove external reading in this work.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the corresponding preserved-summary information was recorded; detailed original materials remain unread and existing content review is incomplete. External abstracts, full texts, registration, plans and COI are unread with no access attempt; source-link operation was not tested. Existing content review remains incomplete.
Reason for missing information: External abstracts, full texts, registration, plans and COI are unread with no access attempt; source-link operation was not tested.
Required materials and conditions: Access status of summaries, external originals, registration, protocol, SAP and COI
Materials to obtain first: User-provided original materials/reading records
Further research: Proposal: Record actual acquisition/reading levels and versions by material; the record includes no new search, calculation or trial.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: The corresponding original materials and analysis scope must be available, with unverified matters distinguishable, for: Access status of summaries, external originals, registration, protocol, SAP and COI. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This production condition links required and currently available materials for the selected question by distinguishing: Access status of summaries, external originals, registration, protocol, SAP and COI.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M04 §4.5–4.6 material collection/selection principles; acquisition/reading separation and hyperlink specifications are internally designed; M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and internal design

Related sources S01 S02 S03 S04 S05

N30 · How are original Korean/English text, reference date, empty values and correction history retained?

Current findings: The parent Korean/English text, axes, F12, Warning,2026-08-26, empty corrections array and empty deliberation string are preserved in the full summary copy. The selected record retains F, note and English wording; absent score/status/axes are not filled from the parent. Absent facet values are not filled with new content.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the corresponding preserved-summary information was recorded; detailed original materials remain unread and existing content review is incomplete. No external update, detailed translation content review or additional correction was performed in this original record. Existing content review remains incomplete.
Reason for missing information: No external update, detailed translation content review or additional correction was performed in this original record.
Required materials and conditions: Preserve original languages,2026-08-26, empty correction/deliberation values, false and unrecorded values
Materials to obtain first: Original correction materials or user correction comments
Further research: Proposal: Link sources/dates of the original version and new production content; the record includes no new search, calculation or trial.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: The corresponding original materials and analysis scope must be available, with unverified matters distinguishable, for: Preserve original languages,2026-08-26, empty correction/deliberation values, false and unrecorded values. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This production condition links required and currently available materials for the selected question by distinguishing: Preserve original languages,2026-08-26, empty correction/deliberation values, false and unrecorded values.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.1, §3.2.1–3.2.4 question-clarification principles; detailed separation rules are internally designed; M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and internal design

Related sources S01 S02 S03 S04 S05

N31 · Are condition application, table production and completed content review separate events?

Current findings: Conditions were saved before recording the frozen production event and a separate application time to create the table. The original model/content/boundary review-pending flags are false, completion is also false, and existing content review remains incomplete. Table production and material-slot counts do not certify clinical review or unique trial/independent participant counts.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the corresponding preserved-summary information was recorded; detailed original materials remain unread and existing content review is incomplete. Existing full content review remains incomplete; QA, screen and link tests were not performed in the original production event. Existing content review remains incomplete.
Reason for missing information: Existing full content review remains incomplete; QA, screen and link tests were not performed in the original production event.
Required materials and conditions: Distinguish conditions saved first, freezing, separate application and existing content-review status
Materials to obtain first: Comments on existing content review and additional preserved materials
Further research: Proposal: Record production versions and user correction comments as history; the record includes no new search, calculation or trial.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: The corresponding original materials and analysis scope must be available, with unverified matters distinguishable, for: Distinguish conditions saved first, freezing, separate application and existing content-review status. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This production condition links required and currently available materials for the selected question by distinguishing: Distinguish conditions saved first, freezing, separate application and existing content-review status.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M04 §4.5–4.6 material collection/selection principles; acquisition/reading separation and hyperlink specifications are internally designed; M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and internal design

Related sources S01 S02 S03 S04 S05